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ABSTRACT
Gamble, Heather Leigh. Ph.D. The University of Memphis. August 2011.
Vaccinating Daughters Against Human Papillomavirus: Comparing Mothers of
Childhood Cancer Survivors with Community Controls. Major Professor: Gilbert Parra,
Ph.D.
Predictors of HPV vaccination intent for daughters were assessed among mothers
of female survivors of childhood cancer and a community control sample of mothers.
Mothers of female survivors of childhood cancer (N = 153) presenting at St. Jude
Children’s Research Hospital for After Completion of Therapy Clinic and a control group
of mothers of healthy adolescent females (N = 44) completed a questionnaire which
included the measurement of demographic and medical information, knowledge of HPV
and cervical cancer, self-efficacy, and health beliefs regarding HPV and cervical cancer.
Current vaccination rates were examined and significant factors that influence mothers’
intent to have their daughter vaccinated against HPV were identified. Results were based
on correlations and linear regression analyses. The constructs measured were entered as
predictors of vaccination intent. For mothers with vaccine naïve daughters, intent to
vaccinate in the future was negatively correlated with daughter’s age and perceived
barriers, and positively correlated with perceived severity, perceived benefits, and selfefficacy. Four factors and two covariates (group, daughter’s age, perceived severity,
barriers, benefits, and self-efficacy) accounted for more than 37% of the variance in
intent. Daughter’s age and perceived benefits demonstrated significant unique effects on
intent to vaccinate. Findings of the current study further our understanding of familial
decision-making about child and adolescent health through identification of factors
influencing HPV vaccination among female survivors of childhood cancer and healthy
iii

controls. Findings will also inform future interventions aimed at increasing HPV
vaccination.
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Vaccinating Daughters against HPV: Comparing Mothers of Childhood Cancer Survivors
with Community Controls
Genital human papillomavirus (HPV) is the most common sexually transmitted
infection. Vaccines to prevent HPV infection have been licensed by the U.S. Food and
Drug Administration (FDA) for use in females and males. Vaccination rates among
females with a history of childhood cancer, a population at higher risk for HPV-related
complications, have yet to be documented. Many survivors are at high risk for HPV
complications because of the direct and indirect effects of cancer treatment; therefore
HPV vaccine uptake is particularly important for females surviving cancer. The
Children's Oncology Group's Long-Term Follow-Up Guidelines for Survivors of
Childhood, Adolescent, and Young Adult Cancer (COG LTFU) recommends HPV
vaccination for all eligible female childhood cancer survivors. Given that the HPV
vaccine was approved for widespread use in females only 5 years ago, and in males only
2 years ago, the extant literature is only beginning to document early rates of HPV
vaccination uptake among the general population. In order to facilitate future vaccine
uptake it is also important to identify factors that influence intentions to obtain the HPV
vaccine. The present study is the first to investigate rates of HPV vaccination among
adolescent female cancer survivors and to compare families of adolescents treated for
cancer to their healthy peers on a number of HPV-related factors. The relations of HPVrelated factors, medical and demographic factors in particular, to mothers’ intent to
vaccinate daughters against HPV were also examined.
Genital HPV is the most common sexually transmitted infection (Sauvageau,
Duval, Gilca, Lavoie, & Ouakki, 2007; Weinstock, Berman, & Cates, 2004).
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Epidemiological studies indicate that approximately 50–70% of sexually active women
contract HPV at some point during their lifetime (Mariam, 2005). More specifically, the
prevalence of HPV has been estimated to be as high as 39.6% among 14- to 19-year-olds
and 49.3% among 20- to 24-year-old sexually active females (Dunne et al., 2007).
Human papillomavirus infection rates are highest in younger women and rise sharply
soon after the mean age of first sexual activity – between 16 and 17 years for females
(Kahn, Rosenthal, Succop, Ho, & Burk, 2002; Winer et al., 2003; Wulf, 2002).
HPV is a double-stranded DNA virus that infects squamous epithelia, and
infection with oncogenic HPV strains is a contributing factor to different types of
anogenital cancer including cervical, vaginal, vulvar, penile, and anal cancers, as well as
head and neck cancers. Of the over 100 identified types of HPV, approximately 40 strains
affect the genital tract (Munoz et al., 2003). Screening for cervical cancer is performed by
Papanicolaou (Pap) testing to identify abnormal cells in the cervix that may lead to
cancer. Some HPV infections may be asymptomatic and most women with HPV
infections have normal Pap test results, as the infection clears without causing any kind
of abnormality (National Cancer Institute, 2007). However, all HPV strains have the
potential to cause abnormal results, indicating development of precancerous cells in the
cervix (American College of Obstetricians and Gynecologists, 2004). Although most
HPV infections will resolve on their own, persistent human papillomavirus infection is a
necessary cause of cervical cancer (Ault, 2007). Although HPV occurs most often in
sexually active adolescents and women aged 15 to 24 years, cervical cancer diagnosis
most often occurs in women over the age of 40, with median age at diagnosis for all
cervical cancer patients being 47 to 48 years (Ries et al., 2006; Watson et al., 2008).
2

Recent efforts to promote cancer prevention and control practices have led to the
development of vaccines against HPV, which are currently available and have been
demonstrated to be clinically effective (CDC, 2007; Harper et al., 2006; Koutsky &
Harper, 2006). In June of 2006, the U. S. FDA approved Gardasil, a quadrivalent vaccine
that protects young women from the 4 types of HPV (HPV types 6, 11, 16, and 18) which
account for 70% of cervical cancers and 90% of genital warts cases (Villa et al., 2005). In
clinical trials, Gardasil has demonstrated nearly 100% efficacy in protecting females
against these 4 HPV types (Villa, 2007; Villa et al., 2006). Additionally, the vaccine is
generally well tolerated and highly immunogenic, indicating good safety and
immunogenicity (Reisinger et al., 2007). In October of 2009, the FDA licensed Cervarix,
a bivalent vaccination against HPV types 16 and 18, and was approved for use in females
aged 10 through 25 years (Centers for Disease Control and Prevention, 2010a).
The FDA approved the Gardasil vaccine for girls and women between the ages of
9 and 26 years (FDA, 2006b). Because it is recommended that girls receive the series of
injections prior to the onset of sexual activity, universal HPV vaccination is
recommended by the Advisory Committee on Immunization Practices (ACIP) for
adolescent females aged 11- and 12-years-old; the series of three injections is
administered over six months and can be started as young as 9 years of age (CDC, 2007).
It is also recommended that young women aged 13 to 26 years who have yet to be
vaccinated or complete the 3-shot vaccine series still receive the HPV immunization known as a catch-up vaccination (CDC, 2007). In the fall of 2009, the FDA also licensed
the HPV vaccine for use in males between the ages of 9 and 26 years for the prevention
of genital warts (FDA, 2010).
3

The projected benefits of mass HPV immunization are considerable. The
American Cancer Society estimates a possible reduction of cervical cancer risk by 70%
or more with the vaccine’s use over many decades (Saslow et al., 2007). Such a decline
in cervical cancer rates will depend on the number of carcinogenic HPV types targeted by
the prophylactic vaccine, durability of protection, degree of vaccination coverage of the
at-risk population, and whether the medical community and the public continue to follow
recommended screening guidelines (Saslow et al., 2007). Furthermore, published studies
have estimated the HPV vaccine to demonstrate significant cost-effectiveness (Huang,
2008; Markowitz et al., 2007; Zimet, Shew, & Kahn, 2008). Therefore, promotion of
HPV vaccine uptake is critical.
As the human papillomavirus vaccine has been widely available for only five
years, sparse literature exists indicating precisely how many females have received (and
completed) the immunization series to date. Medical audits conducted one year post FDA
approval of the vaccine found that as of early 2008, only 10% of age eligible girls and
young women initiated and only 2% had completed the three-dose series (Sheinfeld
Gorin, Franco, & Westhoff, 2008). Numerous clinical trials were conducted prior to
Gardasil’s approval by the U.S. FDA, and at least 21,000 females were vaccinated over
four clinical trials (FDA, 2006a). In a national study conducted by the Centers for
Disease Control and Prevention (CDC) to estimate vaccination coverage among
adolescents, it was recently reported that 44.3% of adolescents aged 13-17 years received
at least one dose of the HPV vaccine series and 26.7% completed the 3-dose vaccine in
2009 (Centers for Disease Control and Prevention, 2010b).
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Certain populations are at an increased risk for HPV infection and HPV-related
health problems. For example, the prevalence of cervical squamous intraepithelial lesions
and the incidence of cervical cancer caused by HPV are higher among women who are
human immunodeficiency virus (HIV)-positive (Palefsky, 2007, 2009). Similarly,
patients who receive immunosuppressive therapy following organ transplantation have
shown increased anal intra-epithelial neoplsia due to HPV-infection (Roka et al., 2004).
Due to the direct and indirect effects of cancer treatment and its suppression of immune
functioning, female survivors of childhood cancers are also at increased risk for HPVrelated health consequences (Klosky et al., 2009). Additional research is needed to
understand the current prevalence of HPV vaccination, particularly among populations at
high risk for HPV infection and related complications.
Female Survivors of Childhood Cancer
The HPV vaccine is an important advancement for public health with specific
benefits relating to the primary prevention of cervical and other cancers. Research must
focus on understanding the factors which relate to HPV vaccination particularly among
high-risk populations such as groups who are immunocompromised or are less likely to
engage in Pap screening as recommended. Female survivors of bone marrow
transplantation as part of cancer treatment are at significantly increased risk for abnormal
Pap test results, precancerous markers of cervical cancer known as cervical dysplasia, and
second cancers including cervical cancer (Klosky et al., 2009). As a result, study of HPV
vaccination intent and completion is needed among female survivors of childhood cancer,
who are at greater risk for HPV-related complication due to altered immunity post cancer
treatment, particularly for those who have experienced bone marrow transplant.
5

Initiation of the immune response to HPV infection is largely orchestrated by
epithelial cells within the lower genital tract. Via pathogen recognition, expression of
antimicrobial mediators, and production of cytokines and chemokines that direct the
immune response, genital tract epithelial cells play a key role in immunity to HPV
(Quayle, 2002). Cancer patients treated with therapies toxic to mucosal surfaces, such as
anthracyclines and radiotherapy, may be more prone to HPV infection simply on the
basis of impaired genital tract epithelial cell function. Survivors with chronic graftversus-host disease that involves the genital tract mucosa may also have impaired
epithelial cell function. When considering the potential for an underlying genetic
predisposition to malignancy in patients already treated for cancer during childhood, one
can argue it is essential to study factors relating to intent to receive and completion of the
HPV vaccine in this group.
In a study examining second malignancies among 3,182 children who underwent
allogeneic bone marrow transplant as part of treatment for acute lymphoblastic leukemia,
researchers reported that the estimated cumulative risk for a new solid cancer was 11%
by 15 years after transplant, which represented a 34-fold increased risk compared with
expected population-based rates (Socie et al., 2000). Sasadeusz and colleagues (2001)
documented a significantly higher rate of cervical cytological abnormalities in recipients
of both allogeneic and autologous transplants when compared to the general population.
The proportion of abnormal Pap smears is typically 3% to 6% among healthy women;
however, for women 3 years post bone marrow transplantation, disproportionate rates of
abnormal Pap smears ranged from 14% to 54% and from 4% to 33% for allogeneic and
autologous transplant recipients, respectively (Sasadeusz et al., 2001).
6

In a recent study of 38 females followed 7 years after allogeneic transplant, 43%
had abnormal Pap cytology smear findings, with 20% experiencing HPV-related highgrade (and 14% experiencing low-grade) squamous intraepithelial lesions (Savani et al.,
2008). Furthermore, those women experiencing chronic GVHD post-transplant that
required prolonged systematic immunosuppressive therapy for >3 years were at the
highest risk for dysplasia and more aggressive abnormalities of the cervix. Finally, a
retrospective study examining the occurrence of new solid cancers among 2,129 patients
who underwent bone marrow transplantation between 1976 and 1998 reported that the
cumulative probability for developing a solid cancer was nearly 15% at 15 years after
bone marrow transplant (Bhatia et al., 2001). More specifically, transplant recipients had
a 13-fold increased risk for the development of cervical cancer compared with expected
population-based rates.
These findings may be explained by immunosuppression that permits persistent
HPV replication that otherwise would not occur. Indeed, there is evidence in other
settings such as renal transplantation that immunosuppression is associated with a greater
incidence of HPV infection and cervical intraepithelial neoplasia than is seen in age- and
parity-matched controls (Seshadri, George, Vasudevan, & Krishna, 2001). Women with
Hodgkin lymphoma and those treated with pelvic irradiation are also more susceptible to
HPV-related complications, likely due to compromised immune functioning (Klosky et
al., 2009). In the largest study of HPV infection among women with Hodgkin lymphoma
performed to date, a retrospective review of medical charts of 666 patients consecutively
treated at The University of Texas M. D. Anderson Cancer Center between 1963 and
1982 revealed that among the 85 study participants, 46% had HPV infection and related
7

neoplasia of the cervix or anogenital region (Katz, Veanattukalathil, & Weiss, 1987).
Additionally, women treated with pelvic irradiation are significantly more likely to
experience HPV-related cervical and vaginal dysplasia and carcinomas of the genital
tract, which are attributed to recurrence of original malignancy, mutation of
cervicovaginal mucosa cells due to radiation exposure, natural HPV dysplastic processes,
or a combination of these mechanisms driven by treatment-induced immunosuppression
(Fujimura, Ostrow, & Okagaki, 1991).
In sum, there is mounting evidence of increased risk for HPV-related health
consequences for females with history of Hodgkin lymphoma, those treated with pelvic
irradiation, and those who have undergone bone marrow transplant. As of yet, it is
unclear is this added risk will extend to all forms of childhood cancers or all methods of
childhood cancer treatment. It is nonetheless important to address the potential protective
health benefits HPV vaccination may offer adolescent female childhood cancer survivors
who are at increased risk for HPV-related complications.
In addition to treatment-related predisposition, survivors of childhood cancer also
engage in behaviors which increase their risk for HPV infection and complications. For
example, survivors of childhood cancer are also at increased risk for infertility, and
female survivors who perceive themselves to be infertile may be at increased risk to
engage in riskier sexual behaviors including lack of birth control use (Zebrack, Casillas,
Nohr, Adams, & Zeltzer, 2004). Relatedly, health care screening utilization in
survivorship has been an issue among female survivors of childhood cancer as they are
less likely than their healthy siblings to have had a recent Pap smear (Hudson et al., 2003;
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Oeffinger et al., 2004; Yeazel et al., 2004), with Hispanic survivors having been the least
likely to have had a Pap test within the last 3 years (Castellino et al., 2005).
Cognitively speaking, inattention and hyperactivity are commonly reported late
effects of childhood cancer treatment. These symptoms have been associated with
increased risky sexual behaviors, such as engagement in casual sex and infrequent
condom use, among young adults diagnosed with Attention Deficit Hyperactivity
Disorder (ADHD) as children (Flory, Molina, Pelham, Gnagy, & Smith, 2006). In a
comparison of adolescents and young adults that had been diagnosed with ADHD as
children within a community control group, a greater percentage of the hyperactive group
had become parents at follow-up and had been treated for a sexually transmitted disease
(Barkley, Fischer, Smallish, & Fletcher, 2006). Engagement in risky sexual behaviors
could place survivors with problems with inattention/hyperactivity at greater risk for
contracting sexually transmitted infections such as HPV.
Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and
Young Adult Cancers have been developed by the Children’s Oncology Group (2006) and
serve as the gold standard in regard to the management of late effects that may arise due
to treatment of pediatric cancer. The recommendations, resulting from thorough literature
review and collective multidisciplinary clinical experience, are intended to increase
awareness of potential late effects and to standardize as well as improve follow-up care
for survivors of childhood cancers. In March of 2006, the second version of these
guidelines was published based on updated research findings related to late-effects of
pediatric cancer treatment, and a third version of these guidelines was released in October
2008. Included in these guidelines are recommendations for health counseling regarding
9

the benefits of HPV vaccination for female patients who have survived childhood cancer.
The endorsement of the HPV vaccine by the panel generating the COG LTFU Guidelines
is a testament to the importance of the HPV vaccine in this relatively high-risk
population. Indeed, medical, behavioral and cognitive late effects of cancer treatment
place survivors of childhood cancer at increased risk for HPV-related complications, and
identifying factors which influence familial decisions to obtain HPV vaccination is
warranted in this population. The present study examined the predictive influence of the
factors discussed below for intent to have daughters vaccinated among mothers of
understudied target populations by comparing at-risk youth with healthy peers. Such
comparisons will address differences in predicative factors for intent to vaccinate and will
assist in tailoring future interventions to promote HPV vaccinations among high-risk
populations.
Influential Factors on Intent to Vaccinate Daughters for HPV
To facilitate future vaccine uptake it is important to identify factors that influence
intentions to obtain the HPV vaccine. Immunization against HPV is likely a familial
decision-making process. Parents/caregivers often determine whether to vaccinate their
daughters and therefore are salient to the vaccine’s utilization. Parents are their children’s
and adolescents’ primary means for obtaining health care, as states conventionally
recognize the right of caregivers to determine health care decisions on their children’s
behalf (Boonstra & Nash, 2000).
Because the vaccine for HPV is relatively new (approved for use among females
by the FDA June, 2006), little is known about the complexity of familial and other factors
which may affect decision-making regarding the HPV vaccination, particularly among
10

high risk populations which may be at relatively increased risk for HPV-related
complication. Vaccination rates among high risk populations are unknown, and there is a
need for greater understanding of the complicated decision-making process for families
to vaccinate daughters against HPV, as it not only involves issues related to vaccination
but also adolescent sexual behavior. In a recently developed conceptual model (Gamble,
Klosky, Parra, & Randolph, 2009), guided by the Health Belief Model, Theory of
Planned Behavior, and Social Learning Theory, it was proposed that the following
variables may have direct predictive influence on mothers’ intent to have daughters
vaccinated for HPV: Health Belief Factors, Cues to Action including Sexual
Communication with Daughters, Knowledge of HPV-Related Health Risks, SocioEnvironmental Factors, Self-Efficacy, and Medical and Demographic Factors. Appendix
A illustrates the conceptual framework for understanding familial decision-making as it
relates to HPV vaccination. Given the large number of factors that may contribute to
intent to vaccinate daughter’s for HPV, and the lack of research pertaining to HPV
immunization among cancer survivors, the focus of this paper has been narrowed to
include medical and demographic factors, health beliefs, self-efficacy, and knowledge of
HPV and cervical cancer. Focusing on these more basic yet relevant factors is a starting
point to identify those most influential in predicting HPV vaccination among families
whose daughters have survived childhood cancers. Future studies will continue to further
examine additional constructs within the conceptual model.
Completion of HPV immunization is first influenced by intentions to receive the
HPV vaccine. The conceptual model helps to identify significant predicting factors that
influence mothers’ intent to have their daughters vaccinated for HPV. The Theory of
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Planned Behavior proposes that an individual’s attitudes toward a behavior, perceptions
of the beliefs of significant others (norms), and perceived control over the behavior
influences his or her behavioral intent, which in turn drives engagement in the actual
behavior (Ajzen, 1991). Such a theory assumes behavioral intention is the most
significant determinant of engaging in a behavior, with intent initially influenced by
personal evaluation of a behavior and beliefs about whether important people would
approve or disapprove of the behavior (Rimer & Glanz, 2005). In other words, multiple
factors influence HPV vaccine intent, which subsequently predicts HPV vaccine
completion. Numerous factors likely fall between HPV vaccine intent and subsequent
completion of vaccination. However, this exploratory study will focus exclusively on
factors predictive of mothers’ intent to have daughters vaccinated for HPV, rather than
those which influence actual immunization implementation. In order to promote the
vaccine among those who have yet to initiate HPV immunization, it is important to assess
future intent to vaccinate and identify factors that predict intentions of getting the
vaccine.
Health Beliefs Factors
The Health Belief Model, previously applied to a number of health behaviors
including vaccination and contraceptive practices, proposes four primary constructs that
aid in accounting for people’s readiness to act (Rimer & Glanz, 2005). They are
perceived susceptibility, perceived severity, perceived barriers, and perceived benefits
(Glanz, Rimer, & Lewis, 2002). Two additional constructs, cues to action and selfefficacy, have been added in recent years; however, there has been less empirical support
in studying these last two factors as part of the Health Belief Model. Within the
12

conceptual model, the health belief factors are largely made up of components from the
Health Belief Model, as these constructs have previously been demonstrated to influence
HPV vaccine acceptance (Brabin, Roberts, Farzaneh, & Kitchener, 2006; Gerend, Lee, &
Shepherd, 2007), but may also include may include attitudes and beliefs held by mothers
regarding immunization. Perceived susceptibility is one’s subjective perception of the
risk of contracting a health condition, such as HPV or cervical cancer. For example, how
likely is my daughter to become infected with HPV? Denial of any need to vaccinate
daughters has characterized parental resistance to vaccinating daughters (Constantine &
Jerman, 2007). Perceived severity is one’s opinion of how serious a condition and its
consequences are. For example, parents may question the severity of treatment for their
daughters’ HPV-related conditions, or social consequences such as disclosure of HPV
infection to sexual partners, health care professionals, and insurance companies. Applied
to the HPV vaccine, perceived benefits would include reducing a daughter’s risks of
contracting HPV thus reducing her chance of developing cervical cancer. Perceived
barriers are opinions on the tangible, as well as psychological, costs of obtaining HPV
vaccination for one’s daughter including pain associated with HPV injections, financial
costs, perceptions of side-effects and unknown risks. Belief that HPV immunization
would promote earlier initiation of coitus and encourage sexual activity has characterized
the opposition that some parents have to the vaccination (Brabin et al., 2006).
Knowledge of HPV-Related Health Risks
Knowledge of HPV and its link to cervical cancer likely affects intention to
vaccinate. Mothers are more knowledgeable of HPV health risks when they understand
HPV transmission, are educated on the link between HPV and cervical cancer, and are
13

familiar with HPV treatment and vaccination safety and efficacy. Low levels of HPV
knowledge have been observed among parents and adolescents, as few have heard of
HPV or a vaccine. Prior to HPV vaccination approval, Brabin et al. (2006) surveyed
parents regarding potential acceptance of such a vaccination. Findings indicate that few
parents knew of HPV or a vaccine for HPV, however 81% reported they would agree to
have their child vaccinated. Parents with higher knowledge levels report greater
acceptance of the vaccine, whereas lack of disease-specific knowledge and questions
about vaccine safety have been linked to rejection of vaccination against STIs.
Self-Efficacy
Another proposed influence on HPV vaccine intentions occurs by means of selfefficacy. As it relates to the Health Belief Model, self-efficacy is one’s confidence in her
ability to successfully take action. Self-efficacy is not only a component of the Health
Belief Model but also a construct of Bandura’s Social Cognitive Theory, a theory which
may be relevant in health behavior (as cited in Glanz et al., 2002). Self-efficacy in Social
Cognitive Theory is “the person’s confidence in performing a particular behavior and in
overcoming barriers to that behavior” (Glanz et al., 2002, p. 169). Little empirical
research has been conducted to examine self-efficacy factors linked to HPV vaccination.
Proposed examples of mothers’ self-efficacy are perceived ability to get daughter to
physician clinic, perceived ability to effectively communicate with daughters about
sexual topics and successfully negotiate with teens regarding completion of the 3-shot
vaccination series. An individual can engage in behavioral changes, even in the face of
obstacles, when she feels a sense of personal agency (Rimer & Glanz, 2005).

14

Medical and Demographic Factors
Parent and adolescent medical and demographic factors are directly related to
intention to seek HPV vaccination. Medical factors represent parent and adolescent health
histories. Demographic factors are population characteristics. Prior research has
examined the association of age, gender, ethnicity, parent education, marital status, and
income with acceptance of HPV vaccination. Previous studies have found no association
between vaccine acceptance and parent socio-demographic factors including ethnicity,
age, and religion (Brabin et al., 2006). Also, while no significant effects for parent age or
gender emerge, Hispanic parents were more likely to endorse vaccination whereas AsianAmerican and African-American parents were less likely to do so (Constantine &
Jerman, 2007). Proposed medical influences on acceptance of HPV vaccination may
include history of cancer, abnormal Pap test results and history of Pap screening, history
of STI testing, and childhood immunization records. Among mothers from a community
health clinic, correlates of HPV immunization acceptability included history of HIV
testing (Gerend et al., 2007). Slomovitz et al. (2006) report that a history of abnormal Pap
tests has not been shown to be associated with women’s acceptance of the HPV vaccine
for either themselves or their children. However, mother’s willingness to vaccinate
offspring against HPV was associated with whether her child had received all previously
recommended immunizations. Evaluating the predictive influence of such demographic
and medical characteristics on vaccination intent was important for the current study, as
these factors have yet to be examined among populations at high risk for HPV-related
health risks.
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Limitations exist within the literature at this time. Most studies have surveyed
parents, adolescents, and physicians regarding attitudes about HPV vaccine acceptance,
yet little is known about intent for getting the vaccine and actual vaccination rates. There
is a lack of application of theory to determine health factors from a range of domains
simultaneously influencing familial decision-making regarding HPV immunization.
Finally, research has yet to examine HPV vaccination issues among those at high risk for
HPV-related complication, such as immunocompromised persons and female survivors of
childhood cancer, in particular.
Present Study
Study Aims
The purpose of the present study was to examine the influence of HPV-related
factors on mothers’ intent to vaccinate daughters against HPV. This study is unique in
that it targeted a population at higher risk for HPV-related complications (i.e., daughters
with a history of childhood cancer) as well as a control group (i.e., healthy daughters).
The present study furthers current understanding of familial decision-making about child
and adolescent health through identification of factors influencing HPV vaccination
among families. This is the first study to compare families of adolescents treated for
cancer to their healthy peers on a number of HPV-related factors, which has implications
for tailoring interventions based on medical risk factors.
Aim 1 of the present study was to examine current HPV vaccination rates among
families with preadolescent/adolescent females. Because little is known about HPV
vaccination rates among female survivors of childhood cancer, comparisons were made
between cancer and controls groups with regard to current vaccination rates as well as
16

intent to vaccinate. Aim 2 was to compare hypothesized influences on intentions to obtain
the HPV vaccine (i.e., medical and demographic factors, cervical cancer/HPV
knowledge, health beliefs, and self-efficacy) between cancer and control groups.
Aim 3 was to assess the relations of medical and demographic factors (i.e.,
maternal age, ethnicity, marital status, education, income, Pap history, STI history,
daughter’s age, daughter’s immunization history, and physician recommendation for
HPV vaccination), cervical cancer/HPV knowledge (i.e., how HPV is transmitted and
risk factors for infection), health beliefs (i.e., perceived susceptibility, severity, barriers,
benefits, and beliefs about decisions), and self-efficacy (i.e., mothers’ ability to talk with
physician, get daughter to medical clinic, complete the 3-shot series) to HPV vaccination
intent among mothers with preadolescent/adolescent daughters. As this study is
exploratory in nature and this area has yet to be studied in this high risk population, no
clear expectations are made with regard to whether mothers of cancer survivors will
vaccinate daughters at higher or lower rates than the healthy population, whether groups
will differ on hypothesized predictors of intent, or which factors will predict intent to
vaccinate daughters against HPV in the future.
Method
Participants
The sample for the present study was comprised of mothers/female caregivers
whose daughters are active patients in the After Completion of Therapy Clinic (i.e., ACT
survivorship clinic) at St. Jude Children’s Research Hospital (SJCRH). The study sample
was also comprised of mothers/female caregivers of daughters without a history of
childhood cancer (i.e., community controls). To be accepted into the ACT clinic, patients
17

must have had a previous diagnosis of malignancy, be 5 years post diagnosis, and
completed cancer therapy at least 2 years previously. Participants for the present study (a)
were mothers/female primary caregivers of active patients who participate in the After
Completion of Therapy (ACT) clinic at SJCRH, (b) had daughters aged 9 to 17 years of
age at time of study enrollment, (c) were proficient in reading and writing English, (d)
were cognitively intact such that the study questionnaire could be understood and
completed, and (e) completed signed informed consent consistent with institutional
guidelines.
In order to obtain a control sample demographically most like the cancer group
based on daughter’s age and mother’s SES and race, each mother recruited for
participation at SJCRH was asked to provide contact information for up to 5
acquaintances, following completion of the study questionnaire. The acquaintances were
also mothers with daughters between the ages of 9 and 17 years-of-age, so that the
primary distinguishing feature of mothers in the community control group and mothers in
the cancer group was presence/nonpresence of daughter’s cancer history. Obtaining a
control group using acquaintance methodology is likely to provide a control sample
demographically most like the cancer group, matched on daughter’s age and mother’s
SES and ethnicity.
Participants in the community control sample (a) were mothers/female primary
caregivers acquainted with participating mothers from SJCRH, (b) had daughters aged 9
to 17 years of age at time of study enrollment, (c) were proficient in reading and writing
English, (d) were cognitively intact such that the study questionnaire could be understood
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and completed, and (e) completed informed consent consistent with institutional review
board guidelines.
Participants included 197 female primary caregivers of daughters, and the
majority (78.7%) of the sample mothers were Caucasian. As most female primary
caregivers (93.4%) reported being the biological mother of the index daughter, for
simplicity’s sake, female primary caregivers are referred to as parents or mothers
hereafter. Mothers’ mean age was 41.75 years (SD = 6.96). Daughters’ mean age was
13.34 years (SD = 2.68). The sample was composed of 153 mothers of childhood cancer
survivors and 44 control mothers of healthy daughters. Mothers of survivors of childhood
cancer ranged in age from 27 to 62 years (M = 41.65, SD = 7.04), and is considered
generally representative of the pediatric cancer population in the US. Daughters with a
history of childhood cancer ranged in age from 9 to 17 years (M = 13.33, SD = 2.71). The
survivor sample consisted of 75.8% whites and 18.3% African Americans. Mothers of
healthy control daughters ranged in age from 29 to 56 (M = 42.09, SD = 6.71). Daughters
without a history of childhood cancer ranged in age from 9 to 17 years (M = 13.36, SD =
2.62). The control sample consisted of 88.6% whites and 2.3% African Americans.
Procedures
St. Jude cancer group study procedures. The present study did not involve any
therapeutic or intervention component, but relied solely on the use of the self-report
questionnaires. Mothers of patients from SJCRH were recruited from the ACT clinic.
Mothers meeting study criteria were recruited consecutively within the time constraints
of the availability of staff. That is, for every opportunity where there was staff available
for recruitment, the researchers attempted to enroll the first available mother meeting
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eligibility criteria, in an effort to reduce selection bias that would favor enrollment of
patients’ mothers known to study staff or recommended by other staff. Eligible SJCRH
mothers who agreed to participate were asked to sign a consent form following an
explanation of the institutional review board-approved study. All participants were
informed that their responses will remain confidential. Mothers who agreed to participate
were asked to complete a battery of paper and pencil questionnaires that assessed factors
predictive of HPV vaccination intent for their daughter as described below. The research
instrument consisted of a self-administered questionnaire inquiring on demographic and
medical information, knowledge of HPV and related health risks, health beliefs about
HPV and vaccination, cues to action, socio-environmental influences, self-efficacy,
sexual communication with their daughter, and vaccination intent for their daughter. The
self-administered questionnaire (see Appendix H) was developed based on a review of
the literature and previous research experience (Brabin et al., 2006; CDC, 2007;
Constantine & Jerman, 2007; Davis, Dickman, Ferris, & Dias, 2004; Dempsey, Zimet,
Davis, & Koutsky, 2006; Gerend et al., 2007; Kahn et al., 2008; Lazcano-Ponce et al.,
2001; Rosenthal et al., 2008). These measures required approximately 30 minutes to
complete. One-hundred eighty-five eligible ACT mothers were invited to participate. Of
those 185, 178 (96%) consented to participate in the study and 153 (86%) completed
study questionnaires were returned. Seven eligible mothers declined to participate, stating
that they were not interested in the study. Please see Appendix B.
Community control group study procedures. Efforts were made to collect a
control sample of mothers of healthy preadolescent/adolescent females demographically
most like that of the families of patients in the ACT clinic. Mothers in the acquaintance
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sample meeting eligibility criteria were invited to participate in the study. Acquaintances
were contacted regarding participation in the study and the study was presented to the
acquaintance control mother. Once the participant provided verbal informed consent for
study participation, the same paper and pencil questionnaires that assess factors
predictive of HPV vaccination intent for their daughter as mentioned above for the
SJCRH parent group (see Appendix H), were sent via postal mail or via a link in a
secured email, which ever was preferred. All participants were informed that their
responses will remain confidential. One-hundred twenty-eight eligible control mothers
were invited to participate. Of those 128, 72 (56%) consented to participate in the study
and 44 (61%) completed study questionnaires. Two eligible mothers declined to
participate, stating that they either did not have time to complete the study measure or
were not interested in participating. Please see Appendix C.
Both SJCRH and control participants were told that they would complete a survey
about cervical cancer vaccination and their daughter’s health and that participation was
voluntary. Mothers were asked to answer all questions about their daughter with a history
of childhood cancer, or for the control group mothers, their daughter closest in age to the
daughter from the referring St. Jude family. A number of procedures were employed to
assure participants that their responses will remain confidential. Identification numbers
rather than participant or patient names were used. After completing the survey,
participants were instructed to seal it in an unmarked envelope. For SJCRH patient
mothers, efforts to ensure confidentiality were made including the use of study code
numbers rather than names, and the provision that information disclosed by mothers
about sexual behavior would not be shared with medical staff or included in the
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daughter’s medical chart. All data was stored on a password protected computer and data
forms were kept in a locked file cabinet. Access to the data was limited to study staff.
Following the completion of the study questionnaire, all mothers received a brief
information sheet outlining the health risks of HPV infection and utility of HPV
vaccination (see Appendix J). The study was approved by both The University of
Memphis and St. Jude Children’s Research Hospital Institutional Review Boards (see
Appendix K).
Measures
Appendix D summarizes the variables studied, where the items are located in the
questionnaire, and the source which guided development of the questionnaire items.
Current Vaccination Status. Daughters’ HPV vaccination status was determined
by one 4-point item. The item read “Has your daughter received the HPV vaccine
(Gardasil or Cervarix)? Mark only one answer.” In terms of responses, the maternal
participant marked 1 of 4 options with the stem, “My daughter has received…” (a) 0 of
the three shot series (has NOT received any of the HPV vaccine), (b) 1 of the three shot
series, (c) 2 of the three shot series, and (d) 3 of the three shot series (has completed the
HPV vaccine). Responses were dichotomized to reflect those who have and have not
initiated HPV vaccination. HPV vaccination status for mothers was also determined by
one 3-point item. Responses were 1 (yes), 2 (no), and 3 (not sure).
Vaccination Intent (Primary Dependent Variable). For those mothers who marked
the letter “A” on the above item indicating that their daughter has received 0 of the 3 shot
series (i.e., has NOT received any of the HPV vaccine), they were asked to complete 4
items assessing intent to vaccinate daughter for HPV. The maternal participant was asked
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to answer 4 items with the stem, “How likely is it that you will have your daughter…” (a)
start the HPV vaccine within the next month, (b) start the HPV vaccine within the next 6
months, (c) start the HPV vaccine within the next 12 months, and (d) vaccinated for HPV
in the future? Each item allowed for responses which ranged from Definitely Will Not (0)
to Definitely Will (6). Items regarding vaccination intent were adapted from questions
used in previous research (Constantine & Jerman, 2007). Due to missing data on some or
all of the 4 intent items, only the final intent item (item “D” above) was used to assess for
any future intent to vaccinate daughters, generating scores which ranged from 0 – 6, with
higher scores indicating greater likelihood to vaccinate their daughter in the future. This
continuous variable of HPV vaccination intent was used as the primary dependent
variable for this study, and was only considered for those who indicated that their
daughters are naive to HPV vaccination.
Medical Care and Demographic Factors. All mothers/female primary caregivers
were asked to provide information on their age, race/ethnicity, marital status, education
level, and annual household income. Maternal marital status was categorized as
“married,” “widowed/divorced/separated,” or “other.” Maternal education level was
measured as a continuous variable by seven items ranging from grade school to graduate
degree. Additionally, annual household income for each participant was assessed using
sixteen items ranging from $0-$9,999 to more than $150,000. Items requesting
demographic background were adapted from previous research instruments (Brabin et al.,
2006; Constantine & Jerman, 2007; Dempsey et al., 2006).
Maternal medical background included mothers’ history of Pap testing and STI,
including HPV infection and cervical cancer. One item assessed whether daughters have
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received all recommended childhood vaccinations. A final item assessed whether or not
daughter’s doctor has recommended that she receive the HPV vaccine. Responses for all
medical background items were 0 (no) and1 (yes). Items regarding mothers’ history of
STI, and abnormal Pap test were adapted from previous self-report questionnaires
(Rosenthal et al., 2008).
General Knowledge of HPV and Related Risk Factors. Knowledge of HPV,
cervical cancer, and HPV vaccination was measured using items adapted from previous
work by Brabin and colleagues (2006) and from the CDC’s website for HPV vaccination
information (CDC, 2007). Ten multiple choice items were used to assess mothers’
knowledge of HPV-related health risks. Participants were provided with questions and
asked to select the correct answer from four possible answer choices. Participants scored
1 or 0 for each response and the number of correct answers was summed to create a
knowledge score for each participant. Scores ranged from 0-10 with higher scores
representing more accurate responses and greater levels of HPV-related knowledge.
Health Beliefs. The four constructs within the Health Belief Model that were
examined included perceived susceptibility to HPV infection, severity of HPV infection,
barriers to HPV vaccination, and benefits to vaccination. Mothers’ perception of their
daughter’s susceptibility to HPV-related health risks compared to other girls her age was
measured by summing five 5-point items, scored 1 (much less likely) – 5 (much more
likely), (e.g., “Compared to other girls her age, how likely is your daughter to have an
abnormal Pap test?”). Scores may range from 5-25 with higher scores indicating greater
perceived susceptibility (α = .94). Mothers’ perception of the severity of HPV and related
health risks for their daughters was measured by summing eight 5-point items, scored 1
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(strongly disagree) – 5 (strongly agree), (e.g., “Infection with HPV can lead to a serious
illness.”). Scores may range from 8-40 with higher scores indicating greater perceived
severity (α = .86). Perceived barriers to vaccination was measured by summing twelve 5point items, scored 1 (strongly disagree) – 5 (strongly agree), with one item reverse
scored. An example item stated, “It would be hard for me to find the time to get my
daughter vaccinated for HPV.” Scores may range from 12-60 with higher scores
indicating greater perceived barriers (α = .78). Perceived benefits of vaccination was
measured by summing seven 5-point items, scored 1 (strongly disagree) – 5 (strongly
agree), with one item reverse scored. An example item stated, “The HPV vaccine would
greatly reduce the chance of getting cervical cancer.” Scores may range from 7-35 with
higher scores indicating greater perceived benefits (α = .82). Items assessing health belief
factors were adapted from the HPV Vaccine Health Beliefs Questionnaire (Cox, Cox,
Sturm, & Zimet, 2010), a validated instrument designed to measure the maternal health
belief constructs of perceived severity, perceived vulnerability, perceived barriers, and
perceived benefits/efficacy as it relates to the HPV vaccine. The questionnaire’s
instructions direct participants to respond to items on a Likert-type rating scale which
ranges from “Strongly Disagree” to “Strongly Agree.” The predictive validity of these
health belief factors has been established in their relationships with HPV vaccination
acceptability among mothers of girls aged 11-16 (Cox et al., 2010).
Self-Efficacy. Mothers’ perceived self-efficacy to have daughters vaccinated for
HPV was measured by six 5-point items, scored 1 (strongly disagree) – 5 (strongly
agree). Scores may range from 6-30 with higher scores reflecting greater self-efficacy (α
= .89). An example of an item on this scale asked mothers to respond to the following, “I
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believe that I could get my daughter to the medical clinic.” Items regarding mother’s selfefficacy for vaccinating daughter were adapted from a previous research questionnaire
(Kahn et al., 2008).
Statistical Analysis
Differences between group means of continuous variables were examined using t
tests, and distributions of categorical variables were compared using χ2 analyses.
Specifically, separate tests were conducted to compare the cancer group and control
group on each proposed influence (i.e., medical and demographic factors, cervical
cancer/HPV knowledge, health beliefs, and self-efficacy). Of note, levels of predictor
influences are reported for all participants, not just mothers of vaccine naïve daughters.
Please refer to Appendix E for an overview of these findings.
To examine the third study aim (i.e., to assess the general predictive influence of
medical and demographic factors on HPV vaccination intent), a linear regression analysis
was conducted. The dependant variable in the regression was mothers’ future intent to
have their daughters vaccinated, thus utilizing only data from mothers of vaccine naïve
daughters. Of note, only mothers with vaccine naïve daughters and complete data for all
predictor variables were included for this analysis (n = 84). Zero-order correlations were
first used to examine relations between all predictor variables and the outcome (intent to
vaccinate daughter for HPV), and only predictor variables that had a significant
association with intent (p ≤ .05) were considered in the regression model. Please refer to
Appendix F for an overview of these correlational findings. Each variable that was
associated with intent was included in a linear regression analysis to determine
independent predictors of HPV vaccination intent. In order to control for developmental
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differences as well as group status (i.e., mother of childhood cancer survivor or healthy
control), age of daughter and daughters’ history of cancer status were entered as
covariates. Please refer to Appendix G for an overview of the regression results.
Statistical analyses were performed using SPSS version 19.0.
Results
Differences between Cancer and Control Groups
The first set of analyses will address Aim 2, which was to compare differences in
hypothesized influences on intentions between cancer and control groups.
Demographic & Medical Factors. Findings indicated that there were differences
between cancer and control groups with regard to racial/ethnic background. Specifically,
the mothers of cancer survivors group included significantly more minorities than the
mothers of healthy controls group, as 9.3% of the control sample and 23.7% of the
survivorship sample were comprised of participants of minority ethnic backgrounds.
Groups did not differ based on maternal age nor on daughters’ age. Groups did not differ
significantly based on mothers’ marital status. No differences in educational background
were found between mothers in the control sample and mothers of cancer survivors.
No differences in annual household income were reported between the control
mothers and mothers of cancer survivors. Of note, differences in annual income were
found between white and minority mothers, with white mothers reporting higher annual
income, t(181) = -3.62, p < .01.
With regard to maternal medical care, 71.1% (n = 140) of mothers reported
receiving annual Pap tests (68.6% of survivorship mothers and 79.5% of control
mothers), and 41.6% reported having ever had an abnormal Pap smear result (39.2% of
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mothers of survivors and 50% of mothers of healthy controls). There was no significant
difference in receipt of annual Pap test or abnormal Pap test results between groups.
Further, 15.2% of mothers reported ever having a STI, 6.6% endorsed ever having an
HPV infection, and 9 mothers (4.6%) reported a personal history of cervical cancer.
There was no significant difference in history of STI or HPV infection between groups.
No difference was found in maternal history of cervical cancer between groups.
An overwhelming majority of mothers (93.9%) reported that their daughter had
received all recommended childhood vaccinations, and only 44.7% of mothers endorsed
that their daughter’s doctor recommended vaccinating for HPV. There was no significant
difference between groups in receipt of childhood vaccinations or physician
recommendation of HPV vaccination.
Knowledge of HPV & Health Belief Factors. The sample as a whole was
relatively unknowledgeable regarding HPV and HPV-related health risks (N = 197, M =
6.13, SD = 1.64). No significant difference was found between groups on HPV-related
knowledge scores. Mothers of cancer survivors reported significantly greater perceived
susceptibility to HPV and significantly less perceived severity for HPV and related health
risks for their daughters than mothers of healthy control daughters. Mothers of childhood
cancer survivors did not endorse greater perceived barriers or benefits to HPV
vaccination for their daughters than mothers of healthy daughters. With regard to
mothers’ self-efficacy to vaccinate daughters, mothers of cancer survivors reported no
significant differences in perceived self-efficacy to vaccinate than mother’s of healthy
control daughters. Appendix E also illustrates these findings.
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HPV Vaccination Rates and Intent
The next set of analyses will address Aim 1 of the present study, which was to
compare cancer and control groups with regard to current HPV vaccination rates as well
as intent to vaccinate in the future.
Vaccination Status. Daughter’s vaccination status will be described first for the
entire sample of participating mothers, followed by the sample of mothers of childhood
cancer survivors, and control mothers. Of all mothers participating in the present study (N
= 197), 65.99% (n = 130) reported that their daughter has not received the HPV vaccine
series, 32% (n = 63) reported that their daughter had either initiated or completed the
HPV vaccine series, and 2.0% (n = 4) of mothers did not answer this item. Of those
daughters who initiated vaccination, 27% (n = 17) had received 1 of 3 shots, 14.3% (n =
9) had received 2 of 3 shots, and 58.7% (n = 37) of daughters had received all 3 HPV
vaccine shots and completed the vaccine series.
Of all mothers participating in the present study (N = 197), 95.9% (n = 189)
reported that they had not received the HPV vaccine personally, 2.0% (n = 4) reported
having personally received the HPV vaccine series for themselves, 1.5% (n = 3) reported
they were not sure whether or not they have received the vaccine, and 0.5% (n = 1) of
mothers did not answer this item.
Of the mothers of daughters with a history of childhood cancer (N = 153), 64.7%
(n = 99) reported that their daughter had not received the HPV vaccine series, 32.7% (n =
50) reported that their daughter had either initiated or completed the HPV vaccine series,
and 2.6% (n = 4) did not answer this item. Of the survivorship daughters who initiated
vaccination, 30% (n = 15) had received 1 of 3 shots, 10% (n = 5) had received 2 of 3
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shots, and 60% (n = 30) of survivors have received all 3 HPV vaccine shots and had
completed the vaccine series.
Of mothers in the survivor sample (N = 153), 94.8% (n = 145) of mothers
reported that they had not received the HPV vaccine personally, 2.6% (n = 4) reported
having personally received the HPV vaccine series for themselves, 2.0% (n = 3) reported
they were not sure whether or not they had received the vaccine, and 0.7% (n = 1) of
mothers did not answer this item.
Additionally, 70.5% (n = 31) of control mothers reported that their daughter had
not received the HPV vaccine series, whereas 29.5% (n = 13) reported that their daughter
had either initiated or completed the HPV vaccine series. Of the control daughters who
initiated vaccination, 15.4% (n = 2) had received 1 of 3 shots, 30.8% (n = 4) had received
2 of 3 shots, and 53.9% (n = 7) of daughters had received all 3 HPV vaccine shots and
completed the vaccine series.
Of mothers in the control sample (N = 44), 100% (n = 44) of mothers reported
that they have not received the HPV vaccine personally. A chi-square test was conducted
to evaluate the difference in daughters’ vaccination rate between groups (cancer and
control; Aim 1). There was no significant difference in vaccination rate between cancer
(33% vaccinated) and control (30% vaccinated) groups. Furthermore, no difference was
found in vaccination rates between daughters of Caucasian mothers (29% vaccinated) and
daughters of minority mothers (42.5% vaccinated), χ2(1) = 3.26, p > .05.
Intent to Vaccinate. Recall that of the total sample, 65.99% (N = 130) of
daughters were not vaccinated for HPV. Future intent to vaccinate daughters for HPV
was measured by one item ranging from ‘Definitely Will Not’ to ‘Definitely Will,’ with
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data collected for 120 of the 130 vaccine naïve daughters. No significant difference was
found in future intent to vaccinate for HPV between groups. Appendix E provides an
overview of these findings.
Influences on HPV Vaccination Intent
The final set of analyses address Aim 3, which was to assess the relations of
medical and demographic factors to future HPV vaccination intent. Paring down the
sample to include only mothers with vaccine naïve daughters and complete data for all
predictor variables (n = 84), zero-order correlations examined relations between all
predictor variables and the outcome (intent to vaccinate daughter for HPV). Appendix F
provides an overview of these correlational findings.
Future intent to vaccinate was negatively correlated with daughter’s age and
perceived barriers. Intent to vaccinate was also positively correlated with perceived
severity, perceived benefits, and self-efficacy. Linear regression analysis was used to
determine significant independent predictors of vaccination intent. Each of the five
variables associated with intent (i.e., daughter’s age, perceived severity, perceived
benefits, perceived barriers, and self-efficacy) was included in the regression analysis,
with group status (i.e., mother of childhood cancer survivor or healthy control) and age of
daughter entered as covariates, and future intent to vaccinate for HPV as the dependent
variable. Analyses revealed that the two covariates and four additional variables
accounted for more than 37% of the variance in intent to vaccinate (R2 = .374).
Daughter’s age (β = -0.18, p ≤ .05) and perceived benefits (β = 0.41, p ≤ .01)
demonstrated significant unique effects on intent to vaccinate (see Appendix G).
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The author was also interested in examining whether the relations between
influences and intent were different for mothers in the cancer and control groups. To
investigate this possibility, correlations were examined separately for the cancer and
control groups. For mothers of childhood cancer survivors, future intent to vaccinate was
negatively correlated with daughter’s age (r = -0.33, p ≤ .01) and barriers (r = -0.33, p ≤
.01), and positively correlated with perceived susceptibility (r = 0.28, p ≤ .05) and
benefits (r = 0.48, p ≤ .01). For mothers of healthy control daughters, future intent to
vaccinate was positively correlated with perceived benefits to immunization (r = 0.65, p
≤ .01). In other words, belief that there are advantages to the immunization was related to
intent to vaccinate for both groups of mothers. For mothers of cancer survivors,
specifically, having a younger daughter, perceiving fewer barriers to vaccination, and
belief that their daughter was at increased risk for HPV infection and related
consequences were also related to future intent to vaccinate.
To further determine whether group status moderated these relations, additional
regression analyses were conducted. Using procedures outlined by Aiken and West
(1991) continuous variables correlated with intent were centered, interactions terms were
computed, and separate regressions were run for each interaction and relevant main
effects. The interactions between group status and daughter’s age, perceived
susceptibility, perceived barriers, and perceived benefits were not significant.
Discussion
The present study was conducted to address 3 primary aims: (a) to examine
current HPV vaccination rates as well as intent to vaccinate among families with
preadolescent/adolescent females with and without a history of cancer, (b) to compare
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hypothesized influences on vaccination intentions to obtain the HPV vaccine (i.e.,
medical and demographic factors, cervical cancer/HPV knowledge, health beliefs, and
self-efficacy) between cancer and control groups, and (c) to investigate the relations of
these factors to HPV vaccination intent among mothers with preadolescent/adolescent
daughters.
This study is the first to investigate HPV immunization rates and intentions
among families of childhood cancer survivors, a population at high risk for HPV
infection and complication, and a control group of healthy peers. It also is one of only a
few that tests components of a conceptual model designed to explain HPV vaccine intent.
As no prior studies have examined HPV immunization rates among or intent to vaccinate
childhood cancer survivors, it is important to note that both the survivor and healthy
groups endorsed vaccination completion rates lower than the national average, therefore
raising concern that survivors of childhood cancer, and their acquaintances, are not being
vaccinated as recommended. Results revealed that daughter’s age as well as perceived
severity, benefits, barriers, and self-efficacy correlated with vaccine intent. Younger age
and perceptions of vaccine benefit were also uniquely associated with future intent to
vaccinate. Furthermore, factors which predicted HPV vaccination did not differ for
mothers of childhood cancer survivors and mothers of healthy daughters. Each of the
primary findings is further discussed below.
Examination of HPV vaccination rates among mothers with and without a child
surviving childhood cancer found that only 32% of daughters had either initiated or
completed the HPV vaccine series. Nearly 66% of participating mothers had not
vaccinated their daughter against HPV. Previous reports by the CDC (2010b) indicated
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that 44.3% of adolescents in the U.S. had initiated the 3-dose vaccination series and
26.7% had completed the vaccine in 2009. The present study’s finding of only 18.8% of
daughters completing the vaccine series is therefore lower than the national average.
Results also indicated no difference in vaccination rate between cancer and
control groups, indicating that mothers of childhood cancer survivors and healthy
controls vaccinate daughters at similar rates. This finding indicates that immunization
recommendations are not being met for the general population, and that Long-Term
Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers
are not being followed for female adolescent cancer survivors. Many childhood cancer
survivors, particularly those treated with hematopoietic stem cell transplantation or pelvic
irradiation and those diagnosed with Hodgkin lymphoma, experience persistent immune
compromise, and impaired immune function appears to be responsible for increased rates
of cervical and oral dysplasia (Klosky et al., 2009). As survivors are at increased risk for
HPV infection and related adverse health effects, efforts to improve HPV vaccination in
this population is warranted.
One possible explanation for the relatively low vaccination rate in this study is
that a majority of the study sample was comprised of mothers of adolescent cancer
survivors whose daughters receive a sizable portion of their medical care from the study’s
recruitment facility. As of yet, this medical setting does not offer HPV vaccination;
therefore, mothers would have had to have independently pursued vaccination for their
daughters in medical settings other than the recruitment facility – a potential barrier to
vaccination. Furthermore, if childhood cancer survivors receive additional medical care
from community providers who are aware of the COG LTFU immunization
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recommendations but assume that the patient’s oncologist is administering the vaccine
series, the community clinicians may be less likely to address the HPV vaccination issue
with the patient and her family. The question then arises, if adolescent cancer survivors
were offered the HPV vaccination by their oncologist or other medical providers at
annual ACT visits, would the vaccination rate for survivors then increase or exceed that
of the general population?
Additionally concerning was the finding that the community control sample of
mothers also endorsed vaccination rates lower than the national average. Although it is
unclear why this finding emerged, one possible explanation is the present study’s small
sample size of control mothers (n = 44) is unlikely to be as accurate of a representation of
the general population of adolescent females as the CDC’s sample of over 9,600 females
with vaccination records.
Intent is an indication of a person’s readiness to engage in a particular behavior
(Ajzen, 1991), and a recent study demonstrated high parental intentions to vaccinate
daughters against HPV (Gerend, Weibley, & Bland, 2009). In a sample of first-year
college females, Juraskova and colleagues (2011) reported that when asked whether they
intended to receive the HPV vaccination in the near future, mean intent scores were
significantly higher following receipt of an HPV information leaflet. The present study
assessed mothers’ intent to vaccinate daughters against HPV in the future, and found no
significant difference in future intent to vaccinate for HPV between groups, indicating
that mothers whose daughters have survived cancer intended to vaccinate their child
against HPV at similar rates as mothers of healthy daughters. Consideration should be
made of the fact that mothers of healthy control daughters were recruited as an
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acquaintance sample, and were therefore familiar with the participants in the comparison
group. It is possible that mothers in both groups have similar attitudes toward HPV
vaccination and even those whose daughters receive medical care from providers in their
home community, where HPV vaccinations may be readily available, have decided not to
vaccinate their daughters as of yet. It is important to note that the mean response for
intentions was between ‘Not Sure’ and ‘Likely,’ indicating that, on average, most
mothers are somewhat undecided or are leaning towards potentially vaccinating
daughters in the future.
The advancements in the treatment of childhood cancer have resulted in survivors
living well into adulthood. Given that the median age of cervical cancer diagnosis is
between 47 to 48 years-of-age and that childhood cancer survivors are at increased risk
for persistent HPV infection, there is a need to better understand factors which influence
vaccination intent and to assess for factors that may improve HPV vaccination rates
among survivors. The present study compared all participating mothers in cancer and
control groups for differences on medical and demographic factors, cervical cancer/HPV
knowledge, health beliefs, and self-efficacy because these variables had yet to be
examined, but may have important implications, among survivors of childhood cancer.
In general, few differences between cancer and control groups emerged,
indicating that the acquaintance control sample successfully recruited mothers of similar
demographic backgrounds to the mothers of cancer survivors. Results also indicated that
the two groups were not significantly different with respect to maternal medical care.
Although no significant difference was found between groups on HPV-related knowledge
scores, participating mothers were relatively unknowledgeable regarding HPV and HPV36

related health risks, as mean knowledge levels were fairly low. Previous published
reports have also demonstrated low levels of HPV knowledge among women (Allen et
al., 2009). No differences were found between groups with regard to Health Belief factors
including perceived barriers to HPV vaccination, perceived benefits to HPV vaccination
for their daughters, or mothers’ self-efficacy to vaccinate daughters.
There were some notable differences between groups of mothers. Specifically, the
number of white and minority participants in the cancer and control groups differed
significantly. Although the survivorship group included significantly more ethnic
minority mothers than the healthy control group, the distribution of children diagnosed
with cancer was consistent with the US population. Results also indicated that groups
differed based on perceived susceptibility as well as severity. Mothers of cancer survivors
rated their daughters as more vulnerable to HPV-related health risks than mothers of
healthy control daughters, yet indicated less severity for HPV and related health risks for
their daughters than mothers of healthy daughters. In other words, mothers whose
daughters survived childhood cancer believed that their daughters were more likely to
contract an HPV infection than healthy daughters; however, they also believed HPV
infection to be less severe or pose fewer health consequences to their daughter than
mothers of healthy daughters. This finding may be explained by the fact that survivors of
childhood cancers are indeed at an increased risk for HPV infection due to
immunosuppression, and mothers of survivors are perhaps aware that their daughter’s
compromised immune system places them at higher risk for infections.
Mothers of childhood cancer survivors may also worry that their daughters will
develop a second malignancy. Recently published findings from the Childhood Cancer
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Survivor Study (CCSS) indicate that survivors of childhood cancer maintain a nearly 1 in
10 chance of developing a subsequent neoplasm, and those surviving the first subsequent
neoplasm remain at risk for development of multiple subsequent neoplasms (Armstrong
et al., 2011). It is possible that survivors’ mothers received messages from oncologists
stating that their daughter is more susceptible to contracting illnesses than healthy peers
and HPV infections specifically. Families may gain firsthand experience living with
immunocompromise during treatment for cancer, as it is not uncommon that patients are
required to wear protective masks in order to attend school or interact with peers. This
may also contribute to increased perceptions of susceptibility to infectious disease.
Other factors specific to HPV and STI’s may also contribute to the finding that
mothers of survivors rated their daughters as more susceptible to HPV than mothers of
healthy controls. For example, mothers of cancer survivors may be more aware of the fact
that HPV is the most common sexually transmitted infection or may have a family history
of HPV and/or cervical cancer. It is also possible that mothers of survivors maintain
perceptions of their daughter’s sexual behavior which place their daughter at increased
risk for contracting HPV or perhaps their daughter has already been diagnosed with an
HPV infection.
Less perceived severity for HPV and HPV-related health risks for childhood
cancer survivors may be explained as mothers viewing cancer diagnosis and treatment as
the greatest health risk for their daughters and that HPV infection is less severe in
comparison. In other words, mothers of survivors may have lower HPV-related severity
scores due to an overall sense of perceived invulnerability or resiliency – even if their
daughter contracts an HPV infection, she has successfully conquered cancer once before,
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so HPV is a much less frightening diagnosis and less daunting to treat. A sense of
resiliency in adolescent cancer survivors has been related to quality of decision-making
for risk behaviors (Hollen, Hobbie, Finley, & Hiebert, 2001). Mothers who believe that
their daughter will not engage in risky sexual behavior may also endorse less perceived
severity related to HPV infection. These mothers may already hold the belief that their
daughter’s cancer diagnosis poses serious medical and social repercussions, therefore any
consequences related to HPV infection may seem more tolerable. If mothers of childhood
cancer survivors are unacquainted with anyone with a personal history of HPV infection
or cervical cancer, it is possible that these mothers are also unaware of the consequences
related to HPV infections. It is also possible that mothers of survivors are indeed unaware
of the link between HPV and cervical cancer, or perhaps are aware that many women are
able to clear an HPV infection without serious consequences.
Additionally, survivors of childhood cancer are now living longer and the median
age of CCSS participants is 32 years-of-age, meaning that many have yet to reach an age
when cancer rates begin to rise in the general population (Armstrong et al., 2011),
particularly given that the median age for cervical cancer expression is 48 years.
Consequently, survivor specialists may not be educating their patients on their risk for
cervical cancer, as this has yet to be demonstrated among survivors despite the research
demonstrating their increased risk for HPV-related complications. Unfortunately, given
that childhood cancer survivors are at increased risk for HPV infection and related
complications, their inability to clear an HPV infection may actually pose HPV health
concerns of greater severity. As cervical cancer is one of a select group of cancers for
which risk reduction could occur by behavioral means (e.g., reducing risky sexual
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behavior and completing in HPV vaccination), survivors may be able to alter their risk
for future HPV-related complication.
Further analyses revealed that, of vaccine naïve daughters, future intent to
vaccinate was correlated with daughter’s age, perceived severity, perceived barriers,
perceived benefits, and self-efficacy. All correlations were in the expected directions;
intent was negatively correlated with daughter’s age and perceived barriers, and
positively correlated with perceived severity, benefits, and self-efficacy. Mothers with
younger daughters and those who endorsed greater perceived severity of HPV infection,
fewer perceived barriers to vaccination, greater perceived benefits to vaccination, and
higher levels of self-efficacy had greater intent to vaccinate their daughters against HPV
in the future.
Previous literature has indicated that daughter’s age is related to HPV vaccination
intent; however, unlike in the present study, Reiter and colleagues (2010) demonstrated
older age of daughter to be related to intent to vaccinate in the future. Furthermore,
researchers have also found no differences in intent to vaccinate by daughter’s age group
(Gottlieb et al., 2009). Several hypotheses have been developed in interpreting this
finding herewithin specific to the inverse relationship between age and vaccination intent.
Of note, the cited studies measured daughter’s age as a categorical variable (i.e., 10 to 12
years, 13 to 15 years, and 16 to 17 or 18 years of age), whereas the present study
measures daughter’s age as a continuous variable (9 to 17 years of age). All daughters of
participating mothers were of eligible age to receive the vaccine. Mothers with younger
daughters may have endorsed higher intent to vaccinate in the future because there will
be time for additional studies to evaluate the safety and efficacy of the relatively new
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immunization before their daughter ages out of the recommended window for
vaccination. As the HPV vaccine becomes more widely marketed, it is likely that mothers
with younger daughters have been exposed to more cues to action for the vaccine series
during the timeframe when their daughter is within the recommended age range for
vaccination; perhaps older daughters did not receive key vaccination messages from their
physicians during their preadolescent years when the vaccine was first available, and
have now “aged out” of the 12-13 year age range which is ideal for vaccination.
Additionally, it is possible that the relation between intent to vaccinate and
daughter’s age is mediated by perceptions of daughter’s sexual activity. Mothers may be
confident that younger daughters are not yet sexually active and would therefore benefit
from vaccination; whereas mothers with older daughters may deem vaccination
unnecessary if their daughters are currently sexually active and likely to already have
been exposed to HPV. This should be further examined in future studies. Mothers with
older daughters may require additional educational information regarding the importance
of vaccinating females prior to the onset of sexual activity in order to achieve greatest
protection. Mothers may also benefit from reminders that even if their daughters are
sexually active, it is unlikely that they have been exposed to all 4 strains of HPV against
which Gardasil protects.
The inverse relation between daughter’s age and intent to vaccinate may also be
explained by a developmental shift in responsibility for medical care. Younger daughters
may still receive regular medical care from pediatricians who have likely discussed the
HPV vaccine with the patient’s family. As age increases, so does an adolescent’s input
into her medical care (Humiston & Rosenthal, 2005). With regard to the familial
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decision-making process for children’s healthcare, mothers maintain a certain sense of
influence over younger daughters’ medical care; whereas more negotiating may be
required to convince an older adolescent to provide vaccination assent to initiate and
complete the vaccine series. Furthermore, as children grow older, they are less likely to
attend medical appointments (Ziv, Boulet, & Slap, 1999) and it is possible that older
adolescents are beginning to be seen individually by their primary care physician for
behavioral risk counseling, such that their parent does not have the opportunity to hear
immunization messages from the physician.
The present study’s findings are similar to previous research correlating Health
Belief factors to intent (Gerend et al., 2007; Juraskova et al., 2011; Kahn et al., 2008),
and nearly all health belief factors were included into the regression model. Mothers in
the present study were more likely to intend to vaccinate daughters against HPV if they
held higher beliefs in the severity of HPV infections. This implies that information
regarding the serious health risks that persistent HPV infection poses for their daughter
could be emphasized further in order to encourage mothers to vaccinate their daughters, a
notion especially important to consider for the high risk cancer sample. Furthermore,
when mothers perceived fewer obstacles to obtaining HPV immunizations, they were
more likely to intend to vaccinate daughters in the future.
Mothers were more likely to endorse higher levels of intent to vaccinate in the
future if their perception was that HPV immunization offers protective health benefits for
their daughter. Mothers with higher perceived benefits to HPV immunization may also
hold a belief in the health protection offered by immunizations in general. When
examining individual benefits of the vaccine, mothers rated a reduction in the chance of
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their daughter getting cervical cancer as the greatest benefit, so it may be that mothers
with greater intent to vaccinate daughters also desire to engage behaviors which support a
public health effort to reduce cancers in women. Perceived benefits have previously been
reported as the strongest predictor of HPV vaccine acceptability (de Visser &
McDonnell, 2008; Dempsey et al., 2006), and findings from the present study
substantiate such reports as regression analyses revealed perceived benefits to have the
greatest beta weight among predictors of future HPV vaccination intent.
Similarly, when mothers endorse greater self-efficacy and believe they have the
means and are able to successfully vaccinate their child, they are more likely to intend to
immunize their daughter against HPV in the future. These findings continue to support
the notion that public health efforts and health care providers should focus on addressing
the concerns that mothers have regarding the safety and efficacy of the HPV
immunization while emphasizing the potential health benefits to protecting their
daughters from the serious types of HPV (Dempsey, Abraham, Dalton, & Ruffin, 2009;
Tissot et al., 2007).
Previous studies have demonstrated that strong physician recommendation of the
HPV immunization is related to maternal acceptance of the vaccine (Dempsey et al.,
2009) and that physician recommendation is correlated with vaccine uptake (Gerend et
al., 2009; Reiter, Brewer, Gottlieb, McRee, & Smith, 2009). In the present study,
however, physician recommendation was not found to correlate with future intent to
vaccinate. Perhaps more importantly, fewer than half of all mothers endorsed that their
daughter’s physician had recommended HPV vaccination, despite indicating that their
daughters have received all recommended childhood vaccines. It may be that without a
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medical provider’s suggestion to immunize their daughter, mothers are unaware of the
recommendation that all females receive the vaccine series. In order to enhance
vaccination among childhood cancer survivors, medical providers will need to address
the importance of HPV immunization in this population. Although the current study did
not examine this specifically, it is possible that some mothers received a recommendation
from their daughter’s physician and yet did not vaccinate. Future efforts are needed to
examine differences in those mothers who did/did not receive a vaccine recommendation
and those who did/did not have daughter vaccinated. Such efforts may identify the best
strategy for physicians to utilize when recommending HPV vaccination to mothers in
order to increase the likelihood that they will adhere to the recommendation.
When controlling for daughter’s age and daughter’s history of cancer (i.e.,
childhood cancer survivor or healthy control), a hierarchical linear regression analysis
revealed that younger age and perceptions of increased vaccine benefit uniquely
predicted intent to vaccinate daughters. When predictors were examined separately for
mothers of cancer survivors and mothers of healthy daughters, no group differences
emerged, indicating that factors which influence mothers’ intent to vaccinate healthy
daughters appear to be the same for mothers of adolescent survivors of childhood cancer.
Given that age and perceived benefits were unique predictors of intent, future
interventions aimed at increasing HPV vaccination among the general population as well
as among cancer survivors should seek to highlight the benefits of HPV vaccination,
particularly for older, sexually naïve females. For survivors of childhood cancer, this may
potentially be done during medical visits with her oncologist. It is important for health
care providers to assess mothers’ perceived benefits to HPV vaccination, and seek to
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provide mothers with factual information regarding HPV immunization
recommendations. Physicians are often unable to spend a great length of time with any
one patient and/or family and may turn to clinical psychologists and other health care
providers, trained in motivational interviewing, to assist mothers in creating discrepancy
and resolving any ambivalence regarding vaccinating daughters against HPV.
When interpreting these findings, one should consider the study’s limitations. As
in other cross-sectional study designs, only associations, not causalities, can be
determined between medical, demographic, and health belief factors and intent. Due to
the small sample of this study, results should be interpreted with caution, and future
studies should seek to enroll higher numbers of participants, as there may be advantages
to having a larger control sample of healthy daughters. Larger sample sizes will provide
future studies with greater power to detect differences among groups of healthy females
and those with a history of childhood cancer, and findings will have greater
generalizability. By recruiting a control group of acquaintance mothers, regional
differences in vaccination rates could not be accounted for. Vaccination coverage for 1317 year old adolescents has been shown to vary by state (Centers for Disease Control and
Prevention, 2010b). Institutional review board approval for the present study placed great
emphasis on participant confidentiality and therefore data were not collected with regard
to the control participants’ state of residence; however, given that all demographic
variables save for ethnicity were found to be consistent between groups, this is perhaps
less of a concern for the present study. Future studies may wish to consider examining
regional differences in vaccination rates.
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Additionally, all cancer participants were recruited from a single site. Findings
may not generalize to other pediatric cancer survivors or healthy daughters not
acquainted with a childhood cancer survivor. It is important to note that an emphasis is
placed on research at the recruitment institution used for the present study, and families
of childhood cancer survivors are accustom to completing study questionnaires as part of
their annual visit. There may be potential differences in HPV vaccination completion and
intent between mothers of cancer survivors who did and did not complete this study,
among mothers whose daughters receive oncology care at different institutions, and even
among survivors of differing cancer diagnoses. This study highlights the importance of
recruiting control samples of healthy females from the general population in order to
further examine differences in intent to vaccinate between survivors and the general
population.
Methodological issues, such as the way intent was measured, may not have
allowed significant associations to emerge. The purpose behind measuring intent with
four items was to also gather data related to mothers’ readiness to engage in vaccination;
however, there appeared to be some confusion in questionnaire instructions, as many
mothers did not complete all four intention items. Because a total intent sum score could
not be calculated for all participating mothers with vaccine naïve daughters, the decision
was made to use only the final intent item to measure ‘future’ intent. Mothers who
reported higher intentions to vaccinate daughters within the next month to year were
excluded in this process, thereby possibly deflating actual vaccine intentions. For
example, a mother may have endorsed that she is ‘Very Likely’ to have her daughter
vaccinated within the next month and ‘Definitely Will’ vaccinate her daughter within the
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next 6 months, but then failed to complete the final two intent items. As a result, her data
were not included in the final analyses, although she endorsed high intent to vaccinate her
daughter.
Several improvements should be made for future studies examining HPV
vaccination among survivors of childhood cancer. A longitudinal study design
reassessing vaccination rates among survivors and important factors related to vaccine
intent over time would be beneficial given that HPV vaccination rates and attitudes have
not been assessed among families of childhood cancer survivors until now. Such a design
would also monitor for changes in attitudes toward vaccination and vaccine uptake within
this population. Future studies should also strive for larger sample sizes with more
equivalent numbers of participants in survivorship and control samples.
Comparisons between survivors and healthy adolescent females may continue to
be monitored for any differences that may arise. Future studies should continue to
examine the predictive nature of the factors included in the conceptual model examined
in the present study on intent as well as vaccine initiation and completion. Such studies
should also examine the predictive nature of additional factors not included in the present
study (i.e., cues to action, socioenvironmental factors, sexual communication, time since
diagnosis, as well as treatment intensity) on intent to vaccinate for HPV, as well as
engagement in immunization. Additionally, relations between vaccine intentions and
engagement in vaccine initiation and completion will need to be examined among
childhood cancer survivors.
Mothers’ perceptions of daughters’ sexual behavior may be a key factor to assess
in future studies, as well; as such perceptions may influence mothers’ intent to vaccinate
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daughters against STI’s. Similarly, communication between mothers and daughters in
general, with regard to sexual topics, and with regard to HPV and cervical cancer
specifically should be assessed for its role in vaccinating adolescent females against
HPV.
Future studies may also evaluate the utility of providing mothers with an HPV
information sheet. Providing mothers with factual knowledge regarding HPV health risks
and immunization may influence intentions for vaccinating daughters against HPV in the
future. Mothers can share the fact sheet with partners and significant others, which in turn
may increase the likelihood of discussion of vaccination within partnerships and families.
Adjusting for time since vaccine licensure, it is necessary to test the efficacy of a
knowledge intervention. Future interventions aimed at increasing HPV vaccination rates
among childhood cancer survivors may seek to provide the HPV vaccine series at
pediatric oncology centers for patients who are able to return to clinic for the 3 shot
series. Medical providers at such institutions may also coordinate care with medical
providers at local health care facilities for patient families who are unable to return for
the series of injections.
To further our knowledge base, vaccination intent should be measured in ways
such that more participant data are eligible for inclusion in the analyses. Future studies
should strive to clarify that all items are to be answered, simplify the measurement of
intent by simply assessing future intent with one item, or perhaps utilize the collected
data in a more meaningful way by examining associations of varying levels of intent. The
use of more psychometrically sound and validated instruments of intentions will also be
beneficial.
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As mentioned previously, the literature is beginning to address the increased risk
of HPV related complications among childhood cancer survivors, necessitating additional
research to demonstrate increased rates of cervical cancer in survivors of childhood
cancer as the cohort of survivors reaches ages when cancer rates begin to rise in the
general population. At present, there is a paucity of research establishing the
immunogenicity of the HPV vaccination among immunocompromised populations. In
HIV-infected children, differences have been noted in quadrivalent HPV vaccine
seroconversion, as titers against HPV subtypes 6 and 18 were demonstrated to be 30-50%
lower than age matched controls (Garland et al., 2007; Levin et al., 2010) A Phase II
study is warranted to examine the safety, immunogenicity, and tolerability as well as
scheduling and dosage of the HPV vaccine among childhood cancer survivors.
In conclusion, findings of the current study further our understanding of familial
decision-making about child and adolescent health through identification of factors
influencing HPV vaccination among female survivors of childhood cancer and healthy
controls. Future interventions designed to increase HPV vaccination among childhood
cancer survivors may draw upon the study findings to enhance immunization rates and
mother’s intent to vaccinate daughters in the future.
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Appendix A

Health Belief
Factors
Cues to Action
&
Sexual Communication

Mother’s Knowledge of
HPV-Related Health Risks
Intent to
Vaccinate Daughter
for HPV

HPV Vaccine
Completion

Socio-Environmental
Factors

Mother’s Self-Efficacy
Mother/Daughter
Medical &
Demographic
Factors

Figure 1. Proposed framework of factors influencing decision-making for HPV
vaccination.
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Appendix B

Total number of
eligible patients to
date:
231

Number of patients
not approached for
consent:
46 (20%)

Number of
patients
approached for
consent:
185 (80%)

Why not approached?
1) Pt no‐showed consent visit
(n=20)
2) Cancelled entire visit or
rescheduled for later date
(n=25)
3) Mom was illiterate (n=1)

Number of patients
agreed to
participate:
178 (96%)

Number of returned
questionnaires:
153 (86%)

Number of patients
declining
participation:
7 (4%)

REASONS FOR
REFUSING CONSENT:


Pending Questionnaires:
 Mail (n=5)
 Internet (n=1)
 Not turned in (n=19)

Figure 2. Enrollment report for mothers of childhood cancer survivors.
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“Not interested” in
participating (N=7)

Appendix C
Total Control info
received:
167

Number
determined not
eligible:
34 (21%)

Number
approached for
128/
consent:
162 (97%)

Why not eligible?
4) No daughter between 9‐17
(n=7)
5) Family member (n=3)
6) Phone not in service/incorrect
(n=14)
7) Hung up on/asked to be
removed from contact list
(n=2)
8) No response after 6 calls (n=8)

Number of
eligible controls:
128 (79%)a

Number of controls
agreed to
participate:
72 (56%)

Number of patients
declining
participation:
2 (1%)

REASONS FOR
REFUSING CONSENT:



Number of returned

+ questionnaires:
44 (61%)

“Don’t have time”
(n=1)
“Not interested”
(n=1)

Pending Questionnaires:
 Mail (n=13)
 Internet (n=15)

Figure 3. Enrollment report for mothers of healthy control daughters.
a

Note. Fifty-four eligible controls pending due to on-going attempts to contact for

participation in study.
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Appendix D
Table 1
Variables Studied in HPV Questionnaire
Predictive factors

Health belief factors

Location in

Source or

# of items in

questionnaire

adapted source

scale

pp. 71-73

Cox et al., 2010

Susceptibility: 5

Dempsey et al.,

Severity: 8

2006

Barriers: 12

Gerend et al.,

Benefits: 7

2007
Kahn et al., 2008
Mothers’ self-efficacy

p. 73

HPV knowledge

pp. 67-68

6
Brabin et al.,

10

2006
CDC, 2007b
Demographic &

pp. 65-66

Brabin et al.,

Demographic: 9

medical factors

pp. 78-80

2006

Maternal

Constantine &

medical: 8

Jerman, 2007

Daughter

Dempsey et al.,

medical: 9

2006
Rosenthal, et al.,
2008
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Vaccination status

p. 69

Maternal: 1
Daughter: 1

Vaccination intent

p.70

Constantine &
Jerman, 2007
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Appendix E
Table 2
Demographic characteristics of participants
Mothers of

Mothers of

Statistical test

Survivors

Controls

p-value

N = 153

N = 44

Maternal age

41.65 (7.04)

42.09 (6.71)

t(195) = 0.37, p = 0.71

Daughter age

13.33 (2.71)

13.36 (2.62)

t(195) = 0.66, p = 0.95

Maternal education

3.22 (1.41)

3.48 (1.13)

t(184) = 1.07, p = 0.29

Annual income

5.82 (4.33)

7.17 (4.12)

t(182) = 1.78, p = 0.08

HPV knowledge

6.04 (1.65)

6.43 (1.59)

t(195) = 1.40, p = 0.16

Susceptibility

11.82 (4.72)

9.61 (3.86)

t(181) = -2.75*, p = 0.007

Severity

31.82 (5.25)

34.76 (4.78)

t(181) = 3.25*, p = 0.001

Barriers

24.63 (5.92)

24.95 (6.44)

t(176) = 0.31, p = 0.76

Benefits

23.44 (4.21)

23.67 (4.36)

t(178) = 0.32, p = 0.75

Self-efficacy

25.78 (3.94)

26.51 (3.83)

t(185) = 1.07, p = 0.29

Vaccination intent

3.56 (1.80)

3.94 (2.03)

t(118) = 0.96, p = 0.34

Characteristic
M (SD)

Note. HPV = human papillomavirus.
Characteristics measured as continuous variables.
*

p < .01.
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Appendix F
Table 3
Medical characteristics of participants
Mothers of

Mothers of

Statistical test

Survivors

Controls

p-value

N = 153

N = 44

Characteristic
n (%)
Ethnicitya

χ2(1) = 4.25*

White

116 (75.8)

39 (88.6)

Minority

36 (23.5)

4 (9.1)

Marital statusb

p = 0.04

χ2(2) = 4.57

Married

109 (71.2)

36 (81.8)

Wid/div/sep

22 (14.4)

7 (15.9)

Other

21 (13.7)

1 (2.3)

Vaccine statusc

p = 0.10

χ2 (1) = 0.25

Vaccinated

50 (32.7)

13 (29.5)

Not vaccinated

99 (64.7)

31 (70.5)

Annual Pap testd

p = 0.62

χ2(1) = 1.01

Yes

105 (68.6)

35 (79.5)

No

41 (26.8)

9 (20.5)

p = 0.31

(table continues)
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Table 3 (continued)
Medical characteristics of participants
Mothers of

Mothers of

Statistical test

Survivors

Controls

p-value

N = 153

N = 44

Characteristic
n (%)
Abnormal Pap
resultsd

χ2(1) = 1.37

Yes

60 (39.2)

22 (50.0)

No

86 (56.2)

21 (47.7)

STId

p = 0.24

χ2(1) = .25

Yes

22 (14.4)

8 (18.2)

No

124 (81.0)

36 (81.8)

HPV infectiond

p = 0.62

χ2(1) = 0.001

Yes

10 (6.5)

3 (6.8)

No

128 (83.7)

39 (88.6)

Cervical cancerd

p = 0.98

χ2(1) = 0.76

Yes

8 (5.2)

1 (2.3)

No

139 (90.8)

43 (97.7)

p = 0.38

Daughter received
all immunizationsd

χ2(1) = 1.55

Yes

141 (92.2)

44 (100)

No

5 (3.3)

0 (0)

p = 0.21

(table continues)
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Table 3 (continued)
Medical characteristics of participants
Mothers of

Mothers of

Statistical test

Survivors

Controls

p-value

N = 153

N = 44

Characteristic
n (%)
HPV rec by
physiciand

χ2(1) = .000

Yes

67 (43.8)

21 (47.7)

No

73 (47.7)

23 (52.3)

p = 0.99

Note. STI = sexually transmitted infection; HPV = human papillomavirus; Rec =
recommendation.
Characteristics measured as categorical variables.
a

0 = minority, 1 = white; b0 = widowed/divorced/separated, 1 = married, 2 = other; c0 = not

vaccinated, 1 = initiated/completed vaccine series, d0 = no, 1 = yes.
*

p < .05.
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Appendix G
Table 4
Correlations among Study Measures
Variable

1

2

3

4

5

6

7

8

9

10

11

12

13

1. Intent
2. Knowledge

-0.03

3. Susceptibility

0.06

0.02

4. Severity

0.29**

0.19

0.12

5. Barriers

-0.34**

-0.15

0.05

-0.15

6. Benefits

0.54**

0.14

0.02

0.25*

-0.48**

7. Self-efficacy

0.25*

0.11

0.33**

0.40**

-0.39**

0.26*

8. Annual Pap

0.02

-0.09

0.09

0.11

0.05

0.04

0.04

9. Abnormal Pap results

0.19

-0.16

0.02

-0.04

-0.03

0.08

-0.19

0.13

10. STI

-0.06

0.02

-0.00

0.08

0.22*

-0.31**

-0.06

0.07

0.14

11. HPV infection

0.05

0.26*

0.10

-0.07

0.10

-0.01

-0.13

0.01

0.41**

0.08

12. Cervical cancer

0.09

0.20

0.11

-0.17

0.13

-0.10

-0.05

-0.01

0.27*

0.07

0.47**

13. Daughter immunizations

0.15

0.16

0.02

0.00

-0.09

-0.02

0.09

0.01

0.19

-0.07

0.08

0.05

14. Physician rec HPV vacc

0.18

0.29*

-0.01

0.29**

-0.09

0.14

0.23*

-0.18

-0.12

0.38**

-0.03

-0.01

71

0.01

Note. N = 84. STI = sexually transmitted infection; HPV = human papillomavirus; Rec = recommendation; Vacc = vaccine.
*p < .05. **p < .01.
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Appendix H
Table 5
Regression Analysis for Variables Predicting Intent to Vaccinate Daughter for HPV in
the Future
Predictive factors

β

t

Sig. (p)

Groupa

-0.14

-1.44

.15

Daughter’s age

-0.18

-1.98

.05*

Perceived severity

0.12

1.08

.29

Perceived barriers

-0.09

-0.80

.43

Benefits

0.41

3.89

<.001**

Self-efficacy

0.05

0.42

.67

Note: N = 84
a

0 = mother of healthy control, 1 = mother of cancer survivor.

*

p ≤ .05. **p ≤ .01.

R2 = .374
F(6,77) = 7.67, p < .001.
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Appendix I
Human Papillomavirus (HPV) Vaccination Study

You are being invited to take part in a research study about a family’s decision to have
their daughters vaccinated against the virus that causes cervical and other cancers. This
virus is known as the human papillomavirus or HPV. A goal of the study is to better
understand what parents know about cervical cancer risk and what factors are important
in their vaccination decisions.
As part of the study, you will be asked to fill out this questionnaire. Completion should
take about 15 minutes.
It is entirely up to you whether you decide to take part in this study. If you decide not to
take part in the study, this decision will not affect your daughter’s care at St. Jude. If you
decide to participate, please fill out the questionnaire on your own, in private. You are
free to answer all, some, or none of the questions. You may feel some discomfort while
answering some questions related to HPV, cervical cancer, and other women’s health
issues. Please remember that your answers will be kept private and will not be shared
with your daughter’s medical team. Do NOT put any additional information on the
questionnaire (such as name, date of birth, home address, zip code, or phone number).
Only the participant identification number will be used to link your responses with your
daughter’s medical information. After completing the questionnaire, place it in the
attached envelope. Seal the envelope and give it to a member of our study team. If you
are completing this questionnaire away from the St. Jude campus, please place the
stamped self-addressed envelope into the mail. Thank you in advance for your
consideration of this study.
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Demographic Information
Date Form Completed: __________________
(today’s date)
Please answer the questions below. When lettered options are provided, please circle
your response. When an answer line is provided, please write in your response.

1. How old are you (in years)? ____________
2. What is your Race/Ethnicity? (circle only one response)
1)
2)
3)
4)
5)

Asian or Pacific Islander
Black/African American
Caucasian
Hispanic/Latino
Native American

6) Middle Eastern
7) Biracial or Multiracial - Please
specify: _________________
8) Other - Please specify:
_____________________

3. What is your current marital status?
1)
2)
3)
4)
5)
6)
7)

Married
Widowed
Divorced/separated
Living with a partner, not married
Single, never married, dating
Single, never married, not dating
Other - Please specify: ________________________________________

4. In terms of religious orientation, which group do you most closely identify with?
1)
2)
3)
4)
5)
6)
7)
8)

Catholic
Baptist
Methodist
Presbyterian
Evangelical
Jewish
Mormon/Latter-Day Saints
Muslim

9) Hindu
10) Buddhist
11) Unitarian
12) Agnostic
13) Atheist
14) Episcopalian
15) Other - please specify:
__________________
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5. Please indicate the number of years of education you have completed.
1) Grade school – last grade you completed: ________
2) Some High School – last grade completed: ________
3) High School Diploma or GED
4) Some college – # of years in college: ________
5) Bachelor’s Degree
6) Some graduate work – # of years post college: ________
7) Graduate Degree
8) Other - Please specify: ________________________________________

6. What was your annual household income last year?
1) 0 - $9,999
9) $80,000 - $89,999
10) $90,000 - $99,999
2) $10,000 - $19,999
11) $100,000 - $109,999
3) $20,000 - $29,999
12) $110,000 - $119,999
4) $30,000 - $39,999
13) $120,000 - $129,999
5) $40,000 - $49,999
14) $130,000 - $139,999
6) $50,000 - $59,999
15) $140,000 - $149,999
7) $60,000 - $69,999
16) More than $150,000
8) $70,000 - $79,999
You are a caregiver for a girl who is between 9 and 17 years old. For the remainder of
this questionnaire, she will be referred to as your “daughter”. If your daughter is followed
in the ACT (survivorship) clinic, please answer all questions about your daughter who
is the St. Jude patient. If you do not have a daughter seen in the ACT clinic at St. Jude,
and you have more than one daughter between the ages of 9 and17, please answer all
questions about your daughter who is closest in age to the St. Jude patient who referred
you to this study.
7. What is your relationship to her? (circle only one)
1) Biological Mother
2) Stepmother
3) Adoptive Mother
4) Grandmother
5) Aunt
6) Foster Mother
7) Other - Please specify: ________________________________________
8. How old is your daughter (in years)?: _______________________________
9. What grade is your daughter in at school? ____________________________
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Knowledge
We would like to evaluate your current level of knowledge regarding specific health
topics of importance to women and their families. Please circle the number of the correct
response to each item below. If you are unsure about the correct answer, please give us
your best guess. Mark only one answer per question.
1. The main job of a Pap smear is to screen for _____________.
1)
2)
3)
4)

Diabetes
Ovarian cancer
Heart disease
Cervical cancer

2. _______ can cause abnormal Pap smear results.
1)
2)
3)
4)

Increased caffeine
HPV infection
High cholesterol
Urinary tract infection

3. Which of the following increases your chances for getting an HPV-related cancer?
1)
2)
3)
4)

Smoking cigarettes
Giving birth to many children
Having first sex at a young age
All of the above

4. Which of the following is associated with increased risk for Human Papillomavirus
(HPV) infection?
1)
2)
3)
4)

Having had multiple sexual partners
Drinking after someone else
Having sex more than once a day
Engaging in same sex (e.g., gay or lesbian) activities

5. How common are HPV infections?
1)
2)
3)
4)

Almost no one gets it, HPV is a very rare infection
One-fourth of sexually active people contract HPV in their lifetime
One-half of sexually active people contract HPV in their lifetime
All sexually active people contract HPV during their lifetime

6. HPV is most common among women and men between the ages of _______.
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1)
2)
3)
4)

14 to 24 years
25 to 35 years
36 to 46 years
47 to 57 years

7. How is HPV spread?
1)
2)
3)
4)

Oral – genital contact
Digital (finger) – genital contact
Genital – genital contact
All of the above

8. HPV is the main cause of _____________.
1)
2)
3)
4)

Pregnancy
Genital warts
Kidney stones
Herpes

9. HPV infections can be cured by ____________.
1)
2)
3)
4)

Antibiotics
Steroid shots
Aspirin
There is no cure for HPV infection.

10. Babies can get HPV in their _______ when born to HPV-infected mothers.
1)
2)
3)
4)

Throats
Muscles
Eyes
Feet

78

Vaccination and Vaccine Intent
Now we would like to continue asking you about health topics that are important to
women and their families. There are no right or wrong answers to the following
questions. We would like to know what you think about these important topics. Mark
your response(s) to each item below.
1. Have you previously heard of Gardasil or Cervarix, the vaccines for Human
Papillomavirus (HPV)?
a) Yes
b) No
c) Not Sure
2. Where did you learn about the HPV vaccine? (choose all that apply)
a)
b)
c)
d)
e)
f)
g)

h)
i)
j)
k)
l)

Never heard of the vaccine
Friend
Doctor
Nurse
School teacher
Spouse
Relative

TV Commercials
Internet
Church
Insurance company
Other - Please specify:
________________________

1. Have you personally received the HPV vaccination (Gardasil or Cervarix)?
1) Yes
2) No
3) Not Sure
2. Has your daughter received the HPV vaccination (Gardasil or Cervarix)? Mark only
one answer.
My daughter has received…
1) 0 of the 3 shot series (has not started the vaccine)
2) 1 of the 3 shot series
3) 2 of the 3 shot series
4) 3 of the 3 shot series (has completed the vaccine)
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3. If your daughter has NOT already started the HPV vaccination series, please answer the following
questions:
How likely is it that you will have your daughter…

a. start the HPV vaccine
within the next
month?

b. start the HPV vaccine
within the next 6
months?

c. start the HPV vaccine
within the next 12
months?

d. vaccinated for HPV in
the future?

0
Definitely
Will Not

1
Very
Unlikely

2
Unlikely

3
Not Sure

4
Likely

5
Very
Likely

6
Definitely
Will

0

1

2

3

4

5

6

0

1

2

3

4

5

6

0

1

2

3

4

5

6

0

1

2

3

4

5

6
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Health Belief Factors
1. Please rate the likelihood of the following statements:
Compared to other girls her age, how likely is your daughter…
1
Much
Less
Likely

2
Less
Likely

3
Just as
Likely

4
More
Likely

5
Much
More
Likely

a. to get an HPV infection?

1

2

3

4

5

b. to have an abnormal Pap test?

1

2

3

4

5

c. to get cervical cancer?

1

2

3

4

5

d. to get a HPV-related cancer other than
cervical cancer?

1

2

3

4

5

e. to die from cervical cancer?

1

2

3

4

5

2. Please rate how much you agree or disagree with the following statements:
1
Strongly
Disagree

2
Disagree

3
Neither
Agree nor
Disagree

4
Agree

5
Strongly
Agree

a. HPV can cause cervical cancer.

1

2

3

4

5

b. Infection with HPV can lead to a serious
illness.

1

2

3

4

5

c. HPV infection can cause genital warts.

1

2

3

4

5

d. Women can die from getting infected with
HPV.

1

2

3

4

5

e. Treatment for cervical cancer is difficult.

1

2

3

4

5

f.

1

2

3

4

5

g. Getting HPV would result in social
consequences for my daughter (having to
tell sexual partners, parents, health care
workers, insurance companies, etc.)

1

2

3

4

5

h. Getting HPV would make it difficult for
my daughter to get a husband/partner.

1

2

3

4

5

Getting cervical cancer would affect my
daughter’s future (ability to have children,
sexual functioning, disability).

3. Please rate how much you agree or disagree with the following statements:
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1
Strongly
Disagree

2
Disagree

3
Neither
Agree nor
Disagree

4
Agree

5
Strongly
Agree

a. It would be hard for me to find the time to
get my daughter vaccinated for HPV.

1

2

3

4

5

b. It would be hard for me to take my
daughter to a clinic or doctor 3 times to get
completely vaccinated for HPV.

1

2

3

4

5

c. It would be hard for me to get
transportation to take my daughter for
more than one appointment to get
vaccinated for HPV.

1

2

3

4

5

d. It would be easy to take my daughter to
the doctor’s office to get the 3-shots of the
HPV vaccine.

1

2

3

4

5

e. My daughter experiences pain when she
receives a vaccination shot.

1

2

3

4

5

f.

My daughter is in danger when she
receives a vaccination shot.

1

2

3

4

5

g. The HPV vaccine would encourage my
child to be more sexually active.

1

2

3

4

5

h. Not enough research has been completed
on the safety of the HPV vaccine.

1

2

3

4

5

i.

Not enough research has been completed
on the effectiveness of the HPV vaccine.

1

2

3

4

5

j.

I do not believe in vaccinations.

1

2

3

4

5

k. The HPV vaccine is expensive.

1

2

3

4

5

l.

1

2

3

4

5

Having my daughter vaccinated for HPV
is against my religious beliefs.

4. Please rate how much you agree or disagree with the following statements:
1
Strongly
Disagree

2
Disagree

3
Neither
Agree nor
Disagree

4
Agree

5
Strongly
Agree

a. The HPV vaccine is very effective in
preventing cervical cancer.

1

2

3

4

5

b. The HPV vaccine would greatly reduce the
chance of getting cervical cancer.

1

2

3

4

5

c. The HPV vaccine is very safe.

1

2

3

4

5
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d. The HPV vaccine is very risky.

1

2

3

4

5

e. Getting the HPV vaccine reduces worry about
sexually transmitted infections.

1

2

3

4

5

f.

1

2

3

4

5

1

2

3

4

5

Getting the HPV vaccine reduces worry about
developing cervical and other HPV-related
cancers.

g. Getting my daughter the HPV vaccine
did/would help me to feel like a good parent.

Please rate how much you agree or disagree with the following statements:
Regardless of the decisions I make/ or have made about HPV vaccination, I believe that I
could…
1
Strongly
Disagree

2
Disagree

3
Neither
Agree nor
Disagree

4
Agree

5
Strongly
Agree

1. talk with my daughter’s doctor about this
issue.

1

2

3

4

5

2. discuss this vaccine with my daughter.

1

2

3

4

5

3. discuss this vaccine with my spouse/partner.

1

2

3

4

5

4. pay (or get insurance to pay) for the vaccine.

1

2

3

4

5

5. get my daughter to the medical clinic.

1

2

3

4

5

6. successfully negotiate completion of the HPV
vaccination with my daughter.

1

2

3

4

5
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Are there other things which did/would influence your ability to get your daughter
vaccinated for HPV? If so, what?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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Social and Environmental Influences on Decisions
There are new vaccines that protect against HPV types that cause most cervical cancers.
Some families decide to have their adolescent daughters vaccinated, while others decide
not to. The choice for each family is personal and many different things may influence
the decision. Please answer the following questions so we can better understand how the
decision to vaccinate for HPV is made.
Please answer the following items regardless of whether or not your daughter has been vaccinated.
Please rate how important the following factors were/would be in making HPV vaccine decisions for
your daughter:

1
Very
Unimporta
nt

2
Unimporta
nt

3
Neither
Important
nor
Unimporta
nt

4
Important

5
Very
Important

1. Physician recommendation

1

2

3

4

5

2. TV commercials/media

1

2

3

4

5

3. Family history of abnormal Pap smears

1

2

3

4

5

4. You or anyone close to you having
experienced genital warts

1

2

3

4

5

5. Family history of cervical cancer

1

2

3

4

5

6. Family history of cancer in general

1

2

3

4

5

7. You or anyone close to you having
experienced a sexually transmitted
infection

1

2

3

4

5

8. Your friends’ approval of the HPV
vaccine

1

2

3

4

5

9. Your friends having their daughters
vaccinated for HPV

1

2

3

4

5

10. Required for school enrollment

1

2

3

4

5

11. Spouse/significant other’s approval of
the HPV vaccine

1

2

3

4

5

12. Your religious beliefs

1

2

3

4

5

13. Insurance coverage/cost

1

2

3

4

5

14. Other (please specify):
__________________________________
__________________________________

1

2

3

4

5
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______________________
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1. Does your health insurance cover the HPV vaccination?
1) Yes
2) No
3) Not Sure
4) I do not have health insurance
2. What else would influence your decision to vaccinate your daughter against HPV?
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
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HPV Vaccine Decision-Making
1. Please rate how much you agree or disagree with the following statements:
Who should make the decision to have your daughter vaccinated for HPV?
1
Strongly
Disagree

2
Disagree

3
Neither Agree
nor Disagree

4
Agree

5
Strongly Agree

a. Mother only

1

2

3

4

5

b. Father/spouse/partner only

1

2

3

4

5

c. Daughter only

1

2

3

4

5

d. Parents decide without daughter’s
input

1

2

3

4

5

e. Parents decide with daughter’s
input

1

2

3

4

5

f. Doctors should decide

1

2

3

4

5

g. Schools should decide

1

2

3

4

5

h. Government should decide

1

2

3

4

5

i. Church should decide

1

2

3

4

5

j. Other - Please specify:
_______________________________
_________________________

1

2

3

4

5
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Medical Background
As girls mature, they may begin to visit a doctor specializing in the female reproductive
system. This type of doctor is known as a “gynecologist” or an
“obstetrician/gynecologist,” sometimes known as an OB/GYN. There are many reasons
why females visit these doctors, and by filling out this section, you will help us estimate
how many women are getting screened/tested for cervical cancer, how often
screening/testing is taking place, and even the results of screening/testing. By knowing
this information, we can maximize our chances to help women stay healthy in the future.
The following questions are about YOUR personal medical history. Please circle your
item responses below.
1. Have you ever been to an obstetrician/gynecologist (OB/GYN)?
1) Yes
2) No
3) Not Sure
2. Have you ever gotten a mammogram?
1) Yes
2) No
3) Not Sure
3. Do you get a Pap test every year?
1) Yes
2) No
3) Not Sure
4. Have you ever had an abnormal Pap test result?
1) Yes
2) No
3) Not Sure
5. Have you ever had a sexually transmitted infection (STI)?
1) Yes
2) No
3) Not Sure
6. Have you ever had an HPV infection?
1) Yes
2) No
3) Not Sure
7. Have you ever had cervical cancer?
1) Yes
2) No
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3) Not Sure
8. Have you ever had a Pap smear?
1) Yes – approximate date of last Pap smear (month/year): ____________. At what
age did you get your first Pap smear? ________
2) No
3) Not Sure
The following questions are about YOUR DAUGHTER’S medical history. Please circle
your item responses below.
9. In the last year, how often has your daughter seen her primary care
physician/pediatrician? (Do not include your family’s ACT/survivorship clinic visit
in this total).
1) None
2) 1 to 2 times
3) 3 to 5 times
4) 6 to 10 times a year
5) More than 10 times
6) Other - Please specify: __________________
10. Has your daughter received all recommended childhood vaccinations?
1) Yes
2) No
3) Not Sure
11. Has your daughter ever been to a gynecologist (GYN)?
1) Yes
2) No
3) Not Sure
12. Has your daughter ever had a Pap smear?
1) Yes – approximate date of last Pap smear (month/year): _____________. Age at
which your daughter received first Pap smear: _______
2) No
3) Not Sure
13. Does your daughter get a Pap test every year?
1) Yes
2) No
3) Not Sure
14. Has your daughter ever had an abnormal Pap test result?
1) Yes
2) No
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3) Not Sure
15. Has your daughter ever had a sexually transmitted infection (STI)?
1) Yes
2) No
3) Not Sure
16. Has your daughter ever been diagnosed with an HPV (Human Papillomavirus)
infection?
1) Yes
2) No
3) Not Sure
17. Has your daughter’s doctor ever recommended that she receive the HPV
vaccine?
1) Yes
2) No
3) Not Sure

Please answer the following questions about your daughter:
1
Yes

2
No

3
Not Sure

1. My daughter is allowed to date.

1

2

3

2. My daughter currently has a boyfriend or is in a
committed relationship.

1

2

3

3. My daughter does not have a current boyfriend and is not
in a committed relationship, but she has been in the past.

1

2

3

4. My daughter is currently sexually active.

1

2

3

5. My daughter is not currently sexually active, but she has
been in the past.

1

2

3

6. My daughter is not currently sexually active, but I
anticipate that she will be sexually active before she
completes high school.

1

2

3

91

Maternal-Adolescent Communication
As girls grow up, mothers may talk with their daughters about ways to keep healthy and
safe. Different messages about physical development and sexuality are provided at
different times in a girl’s life. Please answer the following questions so that we can learn
more about how and when these discussions take place.
1
Strongly
Disagree

2
Disagree

3 Uncertain

4
Agree

5
Strongly
Agree

1. I try to see my child’s point of view when we talk
about sex and sexuality.

1

2

3

4

5

2. I talk with my child about HIV.

1

2

3

4

5

3. I talk with my child about preventing pregnancy.

1

2

3

4

5

4. I set rules for my child about sex and sexuality.

1

2

3

4

5

5. I talk with my child about using condoms.

1

2

3

4

5

6. I talk with my child about body changes that
happen in adolescence.

1

2

3

4

5

7. I talk with my child about sexually transmitted
illnesses.

1

2

3

4

5

8. I encourage my child to ask questions about sex
and sexuality.

1

2

3

4

5

9. I think girls should learn about sex before they
start their period.

1

2

3

4

5

10. I think it’s important to wait until girls are
emotionally ready to talk about sex.

1

2

3

4

5

11. I think it’s important to wait until girls are
physically mature to talk about sex.

1

2

3

4

5

12. I talk with my child about sex and sexuality when I
think her friends are becoming sexually active.

1

2

3

4

5

13. I talk with my child about sex any time my child
asks me questions.

1

2

3

4

5
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14. I talk with my child about sex and sexuality when I
think she is becoming sexually active.

1

2

3

4

5

15. I talk with my child about sex and sexuality before
she is going out with friends.

1

2

3

4

5

16. I use my own experiences when I talk to my child
about sex and sexuality.

1

2

3

4

5

17. I expect my child to follow rules that I set about sex
and sexuality.

1

2

3

4

5

18. I let my child talk as much as I do when we discuss
sex and sexuality.

1

2

3

4

5
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HPV Communication
2. Please rate the following statements about discussing the HPV vaccine with your daughter:
Regarding the HPV vaccine, I have told/will tell my daughter…
1
Untrue

2
Somewhat
Untrue

3
Somewhat
True

4
True

a. Nothing

1

2

3

4

b. It is a shot to keep girls healthy

1

2

3

4

c. It is a shot to protect girls from cervical cancer

1

2

3

4

d. It is a shot to protect girls from HPV
e. Other - Please specify: ___________________
_______________________________________

1

2

3

4

1

2

3

4

Please answer the following questions.
1. Currently, adolescent girls can legally receive HPV vaccination without parental
permission/consent.
1) Yes
2) No
3) Not Sure
2. Adolescent girls should be allowed to seek HPV vaccination without parental
permission/consent.
1) Yes
2) No
3) Not Sure
3. Information about the HPV vaccine should be made available to adolescent girls.
1) Yes
2) No
3) Not Sure
4. Who should provide information to adolescent girls about HPV vaccination? (choose
all that apply)
1) Parents
2) Physician/pediatrician
3) Gynecologist
4) School nurse
5) Health class teachers at school
6) Friends
7) Community health center
8) TV Advertisements
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9) Other - Please specify: _______________________
10) I do not think adolescent girls should be provided with information about HPV
vaccination.

Would you be interested in learning about future St. Jude studies which could
include the free administration of the HPV vaccine? Please check one response
below.
_____ Yes
_____ No
_____ Unsure

You are finished with this questionnaire. Thank you for your participation. Your
answers to these questions will help us to better understand how parents make decisions
regarding whether to vaccinate their daughters against cervical and other HPV-related
cancers. Please contact Dr. James Klosky at 901-595-4128 if you have any questions
about this study. Thank you again for participating!
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Appendix J
Information Sheet for
Human Papillomavirus (HPV) Vaccination among Survivors of Childhood Cancer
Study
You participated in a research study about a family’s decision to have their
daughters vaccinated against HPV, the virus that causes cervical cancer. A goal of the
study is to better understand what parents know about cervical cancer risk and what
factors are important in their vaccination decisions. The research staff is sending you this
information sheet to provide you with more information regarding HPV vaccination
among survivors of childhood cancer.
What is HPV?
Genital human papillomavirus (HPV) is the most common sexually transmitted
infection and approximately 50–70% of sexually active women contract HPV at some
point during their lifetime. Any sexually active person - no matter what race, gender, or
sexual orientation - can get HPV. HPV infection rates are highest in younger women and
rise sharply soon after the median age of first sexual activity (which is about 16.9 years
for females). Specifically, the prevalence of HPV has been estimated to be as high as
39.6% among 14- to 19-year olds and 49.3% among 20- to 24-year old sexually active
females.
What are the symptoms of HPV and health consequences?
Some HPV infections may be asymptomatic and other HPV infections can cause
genital warts in men and women. Although most HPV infections are transient (i.e., will
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resolve on their own within 1 to 2 years), persistent HPV infection is a necessary cause of
cervical cancer because 100% of cervical cancers are HPV related. Women are screened
for cervical cancer with Papanicolaou (Pap) testing to identify abnormal cells in the
cervix that may lead to cancer.
There are over 100 types of HPV, and approximately 40 strains affect the genital
tract. Oncogenic HPV strains have been linked to cervical, vaginal, vulvar, penile, and
anal cancers. Cervical cancer is the second most common cancer among women
worldwide and is the leading cause of cancer-related deaths among women in developing
countries. In particular, HPV types 16 and 18 are responsible for 70% of cervical cancers.
The slow progression of abnormal cell growth due to HPV infection leading to cervical
cancer is estimated take 10 to 15 years. Therefore, although HPV occurs most often in
sexually-active adolescents and women between the ages of 15 and 24, cervical cancer
diagnosis most often occurs in women over the age of 40, with median age at diagnosis
being 48 years.
How do people get genital HPV infections?
HPV is spread through direct skin-to-skin contact during vaginal, anal, or oral sex
with someone who has been infected with HPV. This can include oral-genital, fingergenital, and genital-genital contact. A woman is at greater risk for getting HPV-related
cancers if she smokes cigarettes, began having sex at an early age, has had multiple
sexual partners, does not use condoms, and/or has given birth to many children. On rare
occasions, mothers can transmit HPV infections to a newborn during delivery, which can
cause dangerous warts in the infant’s throat.
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Can HPV be treated?
No. There is no cure for HPV. Most genital HPV infections go away as the body’s
immune system clears the infection. Ninety percent of HPV infections go away (or are
cleared from the body) within 2 years. Although the HPV infection itself cannot be
treated, genital warts can be removed with medications or treatments from a physician.
Additionally, if a Pap test reveals precancerous cells in the cervix, this can and should be
addressed immediately.
Can HPV be prevented?
Yes! The only sure way to prevent HPV is to abstain from any sexual activity.
Condoms can provide some, but not total, protection against HPV as condoms do not
cover the entire genital area. Recently, two vaccines to protect adolescents from HPV
have been developed: Gardasil (Merck & Co.) and Cervarix (GlaxoSmithKline). They are
currently available and have been demonstrated to be very safe and clinically effective.
The Advisory Committee on Immunization Practices (the committee that
develops written recommendations for the routine administration of vaccines to children
and adults) recommends routine HPV vaccination for all females aged 11-12 years with 3
doses of the quadrivalent (Gardasil) or bivalent (Cervarix) HPV vaccine. The vaccine can
even be started as young as 9 years-of-age (Gardasil) or 10 years-of-age (Cervarix). The
American Cancer Society guidelines also recommend routine HPV vaccination for all
girls ages 11 to 12 and as early as 9 at the discretion of doctors.
Why is HPV vaccination important for childhood cancer survivors?
Some cancer survivors may have impaired immune systems as a result of their
cancer treatment. And since we rely on our immune systems to clear HPV once infected,
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those with depressed immune function are at greatest risk for HPV-related complications.
As a result, the Children’s Oncology Group has developed Long-Term Follow-Up
Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer, which serve
as the gold standard in the screening for late effects that may arise due to treatment of
pediatric cancer. These guidelines recommend HPV vaccination for all eligible females
surviving childhood cancer.

For more information visit these websites:
American Cancer Society website on HPV vaccination
http://www.cancer.org/docroot/cri/content/cri_2_6x_acs_recommendations_for_hpv_vac
cine_use_to_prevent_cervical_cancer_and_pre-cancers_8.asp
Centers for Disease Control and Prevention website on HPV
http://www.cdc.gov/STD/HPV/STDFact-HPV.htm#Whatis

Thank you again for participating in our study. If you have further questions
concerning this project, please call Dr. James Klosky at 901-595-3581.
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